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 Preface: Overview of my professional path 
In 1991, I graduated from Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa with a 
pre-Bologna degree of Licenciatura in Applied Chemistry – Biotechnology. I completed my pre-graduation 
internship from 1990 to 1991 in Instituto de Tecnologia Química e Biológica (ITQB), Oeiras, Portugal, 
under the direction of Dr. Isabel Sá Nogueira, where I sequenced part of the Bacillus subtilis L-arabinose 
operon.  
During my career of twenty-nine years, I spent the first seven in academic research in various 
institutes and universities. I later shifted to roles in biotechnology industries, specifically in the life 
sciences and medical devices fields, where I have been working for 22 years, currently focusing on the 
combination pharmaceutical and medical device industry.  
Figure A shows my career timeline and details are covered in the following paragraphs. 
 
 
Figure A. Career timeline 
 
 
In the first seven years of my career, I conducted Academic Research studies in the Microbiology 
field, utilizing mainly Molecular Biology methods to study bacteria. My academic work was included in six 
scientific publications in peer-reviewed journals (Appendix A - Personal Publications). 
From 1991 to 1992, I worked as a Guest Investigator in the Microbiology Laboratory of the 
Rockefeller University, New York, USA, under the direction of Prof. Alexander Tomasz. I performed 
analysis of penicillin binding proteins of Streptococcus pneumoniae and Methicillin Resistant 
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Staphylococcus aureus (MRSA), and epidemiological strain typing thorough Pulsed Field Gel 
Electrophoresis. Part of this work is described in Chapter 1. 
In 1993 I returned to ITQB, Oeiras, Portugal, where I had interned before my graduation – this time 
as a Ph.D. student under the direction of Dr. Isabel Sá Nogueira, continuing my Bacillus subtilis L-arabinose 
research. The work performed during my internship prior to graduation and during this period is 
complementary and published together. 
From 1994 to 1997, I worked under the direction of Dr. Eugenie Dubnau at the Public Health 
Research Institute (PHRI), New York, USA (at the time associated with New York University and now part 
of Rutgers University). I was a Research Assistant and studied virulence and antibiotic resistance 
mechanisms of Mycobacterium tuberculosis. This work is reported in Chapter 2. 
In the second span of my career, consisting of twenty-two years, I maintained my Molecular Biology 
focus while switching my activity to roles in the Biotechnology Industry. I performed various functions in 
companies that research, develop and manufacture products for the life science and medical diagnostic 
fields. 
From 1998 to 2004, I performed several roles in the Research and Development and in the 
Production departments at Clontech, Palo Alto, California, USA (acquired by Becton Dickinson Biosciences 
during my tenure, and now part of TakaraBio). I was a Production Supervisor in the DNA Arrays group, 
responsible for launching and managing production of the nylon DNA arrays product lines. I later 
transferred to a Production Scientist role performing investigations in the manufacturing of PCR 
(Polymerase Chain Reaction) related enzymes. In early 2001, I transferred to a Research Associate role in 
the R&D Department, where I cloned, modified, and purified novel enzymes, such as DNA-polymerases 
and Reverse-transcriptases. I also developed and characterized enzymatic systems for PCR, Reverse-
transcription, and real-time PCR. 
From 2004 to 2019 I worked in the Product Transfer Department at Cepheid Inc, Sunnyvale, 
California, USA. I held a variety of titles from Process Development Scientist to Director of Product 
Transfer. Under my tenure, Cepheid expanded from 1 to over 25 product lines, each with multiple sub-
types. One product line specifically is the XpertMTB Assay line for the detection of Mycobacterium 
tuberculosis and antibiotic resistance, which public elements are described in Chapter 3.  
I opted to focus this report on the detection, virulence, and antibiotic resistance of the pulmonary 
infectious agents Streptococcus pneumoniae and Mycobacterium tuberculosis, drawing a unifying line 
from my work at the Rockefeller University, to the PHRI and to Cepheid, Inc. (Figure B. Unifying line 
through pulmonary infectious diseases). Some of the work performed by other colleagues is also 
presented because it is important to justify the conclusions. The work performed by others is identified 





Figure B. Unifying line through pulmonary infectious diseases 
 
 
Leveraging my experience in the management of development and production projects in the 
regulated Molecular Diagnostic field, I recently shifted my career to Project Management in the field of 
Medical Devices/Pharmaceuticals. In January 2020, I completed a Project Manager Professional 
certification, by the Project Management Institute. I am currently a Project Management Consultant at 
AstraZeneca, where I lead teams in the development of combination biopharmaceutical / subcutaneous-
injection device products, supporting device development and all required verification and validation 
studies, clinical trials, and transfers to production. The products mainly consist of accessorized pre-filled 
syringes, auto-injectors and/or pens for home use, which are pre-filled with biopharmaceutical 
therapeutic products such as monoclonal antibodies, and ultimately will provide methods for safe and 
effective deliveries of medications to patients. 
  






Pulmonary infectious diseases, like pneumonia and tuberculosis, have been pervasive throughout 
the world for centuries; they kill millions of people annually worldwide and pose an increased threat 
when associated with antibiotic resistance and viral co-infections such as influenza and, more recently, 
Covid-19.  
This professional activity report summarizes some of my work in the last three decades, using 
biotechnology to type, characterize or detect two major bacterial infectious agents, Streptococcus 
pneumoniae and Mycobacterium tuberculosis. 
Strain typing techniques, like Pulsed Field Gel Electrophoresis and Penicillin Binding Protein 
patterns, were used to identify Streptococcus pneumoniae clones from different geographic areas in the 
early-1990s, showing strong evidence of clonal dissemination locally and across the globe, from Spain to 
Iceland and to the United States. 
In the mid-1990s, an in vivo expression technology system based on a promoter-trap was 
constructed to enable the identification of Mycobacterium tuberculosis genes upregulated in human 
macrophages, through selection for antibiotic resistance. This work led to the identification of eight genes 
likely relevant for Mycobacterium tuberculosis virulence. Several were later confirmed to be required for 
infection or survival in the host. 
A single-step molecular diagnostic real-time PCR assay for the detection of multidrug resistant 
Mycobacterium tuberculosis was commercialized in the late 2000s, with great impact in the detection of 
tuberculosis, especially in developing countries. The mechanism of the assay is presented here as 
published by its inventors, as well as with my role in the industry, from the development of processes for 
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As doenças infeciosas pulmonares, como a pneumonia e a tuberculose, têm tido, durante séculos 
uma prevalência mundial significativa, matando milhões de pessoas anualmente e representando uma 
ameaça crescente quando associadas à resistência a antibióticos ou coinfeções virais, como a gripe e, 
recentemente, o Covid-19. 
Este relatório de atividade profissional resume parte do meu trabalho nas últimas três décadas, 
usando técnicas de biotecnologia para identificar, caracterizar ou detetar dois importantes agentes 
infeciosos de origem bacteriana, Streptococcus pneumoniae e Mycobacterium tuberculosis. 
Técnicas de identificação de estirpes, como eletroforese tipo Pulsed Field e padrões de proteínas 
com afinidade à penicilina, foram usadas para identificar clones de Streptococcus pneumoniae de 
diferentes áreas geográficas no início da década de 90, mostrando forte evidência de disseminação, não 
só a nível local, mas também através do globo, nomeadamente, de Espanha para a Islândia e Estados 
Unidos. 
Em meados da década de 90, um sistema de expressão in vivo foi construído para permitir a 
identificação de genes de Mycobacterium tuberculosis com expressão elevada em macrófagos humanos, 
através de seleção por resistência a antibióticos. Este trabalho levou à identificação de oito genes com 
probabilidade de serem relevantes para a virulência de Mycobacterium tuberculosis; vários 
posteriormente confirmados como necessários para a infeção ou sobrevivência no hospedeiro. 
Mais recentemente, foi comercializado um teste de real-time PCR para diagnóstico molecular de 
Mycobacterium tuberculosis com multirresistência a antibióticos, com grande impacto na deteção da 
tuberculose, principalmente em certos países em desenvolvimento. O mecanismo de deteção é 
apresentado aqui conforme publicado pelos seus inventores, bem como o meu papel na indústria de 
diagnósticos moleculares, desde o desenvolvimento de processos de produção e controle de qualidade, 
até a distribuição em conformidade com os respetivos regulamentos, passando por resolução de 
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1. Introduction 
1.1. Relevance of Streptococcus pneumoniae 
Streptococcus pneumoniae, commonly referred to as pneumococcus, is one of the leading causes 
of pneumonia. It can also co-infect the host as a complication from influenza, when it is especially 
dangerous for the elderly, and it is now believed to have caused much of the mortality during the 1918 
influenza pandemic [1,2]. According to the World Health Organization, pneumococcus is the most 
common cause of bacterial pneumonia in children; pneumonia is the single largest infectious cause of 
death in children worldwide, and in 2017 accounted for 15% of all deaths of children under five years old  
- over three quarters of a million deaths [3]. Recent reports of superinfection with Covid-19 further 
increase the concerns [4,5]. 
Humans are the main reservoir of S. pneumoniae; asymptomatic carriage is commonly found in the 
upper respiratory tract (nasopharynx) of healthy individuals, mainly children. The immunologic 
mechanism that allows disease to occur in a carrier is not clearly understood, but when a predisposing 
condition like pulmonary illness exists, immune dysregulation can occur, and potentially lead to infections 
and diseases such as pneumonia, sepsis, otitis media, conjunctivitis and meningitis [6,7]. 
S. pneumoniae played a significant role in the history molecular genetics. It was discovered 
independently by Pasteur and Sternberg in 1881 [2].  In 1928 Frederick Griffith (Figure 1.1) proved that 
live, harmless S. pneumoniae can be transformed into a deadly strain by combination with an extract from 
heat-killed, virulent S. pneumoniae [8], proving that virulence is conferrable. Further, in 1944, Avery, 
MacLeod, and McCarty (Figure 1.1) showed that the transforming factor in Griffith's experiments was not 
protein, as popular opinion favored at the time, but DNA [9]. 
 
Figure 1.1. Notable scientists in early Streptococcus research 
Left to right: Frederick Griffith, 1877-1941 [10], Oswald Avery, 1877-1955 [11], 





Streptococcus pneumoniae are Gram-positive cocci, often lancet-shaped. They are frequently 
arranged in pairs (diplococci) but can also be found separately or arranged in short chains. S. pneumoniae 
is a facultative anaerobe; in the laboratory, its growth is best in 5% carbon dioxide and requires a source 
of catalase (e.g., blood) to neutralize the large amount of hydrogen peroxide produced by the bacteria.  In 
complex media containing blood, the bacterium has a doubling time of 20-30 minutes at 37°C [14].  On 
blood agar, colonies characteristically produce a green zone due to alpha-hemolysis, which is the partial 
hemolysis of the red blood cells, as opposed to complete hemolysis, or beta-hemolysis (Figure 1.2). Alpha-
hemolysis differentiates S. pneumoniae from the Group A (beta-hemolytic) streptococci, but not from 
Streptococcus viridans, another alpha-hemolytic co-inhabitant of the upper respiratory tract. The 
minimum criteria for traditional identification and distinction of pneumococci from other streptococci 




Figure 1.2. Types of hemolysis 
The use of a blood agar plate to 
visually differentiate the extent of 
hemolysis of the red blood cells. 
Figure replicated from Garner, 
Microbiology Nuts & Bolts [17] 
Figure 1.3. Optochin disk test 
Optochin test for S. pneumoniae using 
optochin disks. Left: S. mitis, resistant 
to optochin with no zone of inhibition; 
Right: S. pneumoniae, susceptible to 
optochin. Figure replicated from 
Centers for Disease Control and 
Prevention [16]. 
 
S. pneumoniae possesses autolysin enzymes which disrupt and disintegrate its cells and kill the 
entire culture when grown to stationary phase. Virtually all clinical isolates of pneumococci harbor this 
autolysin. In the laboratory, cultures start to undergo lysis between 18 and 24 hours after initiation of 
growth under optimal conditions. On agar cultures, colonies initially appear with a plateau-type 
morphology, then start to collapse in the centers when autolysis begins [14]. Autolysins play a major role 
in pneumococcal virulence [18], which is reviewed below. 
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1.3. Virulence factors 
The major S. pneumoniae virulence factors include a polysaccharide capsule that provides 
protection from the host's immune system, surface proteins with various roles from cell adhesion to 
metal ion transport mechanisms, autolysins and other lysis proteins with roles in cell growth, and pili that 
enable S. pneumoniae to adhere to epithelial cells in the upper respiratory tract [6,18–21]. 
Pneumococcus cells possess a capsule of complex polysaccharides on their outer surface, which acts 
as a virulence factor for the organism in several ways: by allowing the bacterium to adhere to host cells and 
cause inflammation/infection, by restricting autolysis and reducing exposure to antibiotics, and by 
preventing recognition and phagocytosis by the host’s immune cells (anti-phagocytosis) [21]. Encapsulated 
strains of S. pneumoniae are found to be 100,000 times more virulent than non-encapsulated strains during 
invasion of mucosal surfaces [14]. The mechanisms of anti-phagocytosis are not fully understood, but there 
are studies showing that the capsule may mask antibody recognition of subcapsular antigens localized on the 
pneumococcal cell wall, as well as prevent the host immunoglobulins that found their way to the 
pneumococcal cell surface from interacting with their receptors on the surface of phagocytic cells, with the 
result that the organisms remain extracellular [21,22]. Additionally, the negative charge that the capsule 
tends to have in many serotypes, may cause electrostatic repulsion, providing a plausible explanation for S. 
pneumoniae’s ability to avoid being trapped by negatively charged mucus layers and phagocytic cells [2,6]. 
Although the polysaccharide capsule is essential for virulence, and is present in all isolates 
responsible for invasive pneumococcus disease in otherwise healthy individuals, it was proven recently 
as non-essential for colonization; non-encapsulated S. pneumoniae (NESp) isolates have both been found 
in up to 19% of asymptomatic carriers, and confirmed to be the cause of non-invasive pneumococcal 
diseases such as otitis media and infectious conjunctivitis. In rare cases, and mainly in immunodeficient 
patients, infection with NESp can also lead to invasive pneumococcal disease [23]. 
In general, autolysins degrade the cell wall of bacterial organisms, ultimately leading to cell lysis. 
These enzymes play roles in a variety of physiological cell functions associated with cell wall growth, cell 
turnover, and cell separation. The N-acetylmuramyl-l-alanine amidase from S. pneumoniae, also known 
as LytA amidase, has been implicated in the pathogenicity of pneumococci by cleaving a specific 
peptidoglycan bond and breaking the cell wall, leading to cell lysis and to the resulting release of 
pneumococcal antigens such as pneumolysin, peptidoglycan, and teichoic acids which are all harmful to 
host cells; these components may help the pneumococci evade the immune system by inhibiting cytokine 
production and blocking the activation of phagocytes [6]. 
Pneumolysin (Ply) is a cytoplasmic enzyme that is released due to the action of surface 
pneumococcal autolysins and has been shown to act as virulence factor through many mechanisms. 
Pneumolysin binds to membranes containing cholesterol, and forms pores which later lead to host cell 
lysis. It also plays a role in promoting the formation of biofilms, it reduces mucus clearance of the 
Introduction 
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bacterium which facilitates the spread of pneumococcal infection, it can interfere with the host’s immune 
system, and can cause DNA damage by dysregulating the production of reactive oxygen species as a result 
of its pore-forming abilities [6]. 
Pili are long, thin hair-like structures that extend outside of the polysaccharide capsule. Pili aid in 
the attachment and colonization of the nasopharynx and lungs of hosts by S. pneumoniae, and help the 
bacteria avoid phagocytosis by host immune cells. There are two main types of pili found on S. 
pneumoniae: pilus-1, which is found in 30% of clinical isolates, and pilus-2 which is only found in about 
16%. Studies have shown that pili are able to stimulate inflammatory responses of the host [6,14,20]. 
1.4. Classification of pneumococcus 
Pneumococcal type-specific antisera were widely used for the treatment of patients in the early 
20th century, and pneumococcus responses to the antisera were used to type the isolates, classified as 
serotypes. Although many serotypes were documented and available, antisera were not always effective 
against all serotypes. The death of Danish Prince Valdemar in 1939, with a novel serotype within 
serogroup 9 which did not respond to then available antisera, precipitated the development of multiple 
serotyping studies, simultaneously in Denmark and in America. The Quellung (swelling) reaction, which 
had been originally developed by Friedrich Neufeld in 1902, was adopted and the Danish system of 
classification was widely accepted throughout the world [2]. The Quellung reaction is based on an 
antigen-antibody reaction between antiserum and the highly antigenic polysaccharide capsule, which 
causes the capsule to appear to swell under microscopical examination (Figure 1.4) [2,14,24]. 
 
Figure 1.4. Microscopical observation of S. pneumoniae in patient sputum. 
S. pneumoniae in patient sputum on microscopic slides, mixed with rabbit antiserum, and stained 
with methylene blue. Type II pneumococcus in sputum is mixed with type I rabbit antiserum on 
the left panel, and with type II rabbit antiserum on the right panel. The right panel shows the 
Quellung reaction (swelling of the capsule). Figure replicated from Sabin, 1933 [24]. 
 
Over 90 different serotypes of pneumococci have been identified, and they differ in prevalence and 
extent of drug resistance [6,25]. The virulence of the polysaccharide capsule is enhanced by the 
pneumococci’s ability to undergo recombination; mutations in the capsule polysaccharide synthesis 
genes (cps locus) promote capsular switching, which can generate novel combinations of serotype and 
genomic backbone, and conferring to pneumococcus the ability to evade the host immune response [25]. 
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1.5. Genetic diversity 
Pneumococci are competent and naturally transformable, readily taking up exogenous DNA and 
incorporating it into the genome by homologous recombination. In laboratory batch cultures, 
competence typically appears suddenly in most or all cells of the culture at some point during 
exponential-phase growth, persists for 10 to 20 min, and then decays rapidly. The induction of 
competence depends on an extracellular protein, named competence factor (CF), which serves as a 
monitor of population density. The state of competence is accompanied by a gross metabolic shift and a 
switch in protein synthesis yielding several competence-specific intra- and extra-cellular proteins [26]. 
S. pneumoniae’s virulence thrives because of the bacteria’s innate ability to acquire new genetic 
material via transformation and recombination. Horizontal transfer of genetic material, not only by 
homologous recombination but also by mobile genetic elements, generally amplifies substantially the 
heterogeneity of the common gene pool, providing a mechanism for capsular switching as described 
above, and advantages for the pathogen to circumvent the effects of vaccines and antibiotic treatment 
through resistance [6,25]. 
1.6. Antibiotic resistance and pneumococcus 
Pneumococci were once among the most highly penicillin-susceptible bacteria, but clinical isolates 
evolved rapidly since the 1970s to contain a higher incidence of penicillin resistance. Contemporary 
strains with high levels of penicillin resistance also tend to carry resistance to other antibiotics, creating 
an additional challenge to treatment [27]. The phenomenon of multi-drug resistance (MDR) is currently 
observed in many other bacterial pathogens including Methicillin Resistant Staphylococcus aureus 
(MRSA) and Mycobacterium tuberculosis [27,28]. According to the United States Center for Disease 
Control (CDC), at least 2.8 million people are infected each year in the U.S. with antibiotic-resistant 
bacteria or fungi, and more than 35,000 people die as a result [29]. 
Penicillin-binding proteins (PBPs) are a group of key proteins with transpeptidase and/or 
glycosyltransferase functions that are essential for bacterial cell wall synthesis, involved in the assembly 
of the peptidoglycan after its precursor is transported from the cytoplasm, across the cell membrane, to 
the outer layers of the cell. PBPs earned their name from their affinity for penicillin and other β-lactam  
antibiotics [30,31].   Penicillin binds to wild type PBPs, preventing peptidoglycan linking in the last stages 
of bacterial cell wall synthesis, weakening the cell wall, and causing bacteria to lyse. Penicillin-resistant 
clones of pneumococci often have altered PBPs with markedly reduced affinity toward the antibiotic 
molecule, and presumably their natural substrates, and therefore producing peptidoglycans of grossly 
abnormal muropeptide composition and branching structure [30–32]. 
Strain Typing Methods 
 7 
2. Strain Typing Methods 
In the work that is reported in this chapter, performed in the early 1990s, three techniques were 
used to type bacterial clones/isolates: Multilocus Enzyme Electrophoresis, Pulsed-Field Gel 
Electrophoresis (PFGE) and analysis of PBP patterns. They are described below. 
2.1. Multilocus Enzyme Electrophoresis 
Multilocus Enzyme Electrophoresis is based on the premise that enzyme modifications alter the 
electrophoretic mobility of proteins. Variations of multiple enzyme loci are assessed by running multiple 
protein separation gels on culture extracts and assaying each gel for specific enzyme activity using 
labeling dyes.  
The variable mobility patterns of each enzyme are assigned an allele type, and an increased 
variability of enzyme configurations is associated with genetic diversity. On the contrary, similar patterns 
are associated with lack of diversity and suggest the possibility of clonality [33,34]. Multiloccus Enzyme 
Electrophoresis experiments were conducted by collaborators in the laboratory of Dr. James Musser 
(Baylor College of Medicine, Houston, Texas), and in B. Spratt's laboratory (Brighton, UK) for the Spanish 
isolates. 
2.2. Penicillin Binding Protein (PBP) patterns 
PBP patterns are known to change dramatically with resistance to β-lactam antibiotics as a result 
of the reduced affinity that most resistant mutants show for those antibiotics [27]. Jabes et al. showed a 
direct correlation between the amount of [3H] (tritiated) penicillin needed to detect most PBPs and the 
minimum inhibitory concentration (MIC), concluding from a relatively large number of isolates that 
increased penicillin resistance trended with decreased penicillin affinity. They found a high multiplicity of 
PBP patterns among highly resistant clinical isolates of pneumococci [35].  
PBP patterns were assayed as described by Williamson et al., by incubating exponential-phase 
cultures of each strain with saturating concentrations of tritiated penicillin ([3H]-benzylpenicillin) to 
radioactively label all PBPs in 10 minutes, followed by lysis, protein separation by SDS-PAGE (Poly-
Acrylamide Gel Electrophoresis) and detection by autoradiography [36].  
2.3. Pulsed-Field Gel Electrophoresis (PFGE) 
PFGE analysis involves the comparison of patterns of discrete fragments of the chromosomal DNA 
of each isolate after digestion with a specific restriction endonuclease, under the premise that mutations 
that create or eliminate specific recognition/restriction sites, or large deletions that change the length of 
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the fragments, should reflect how distant the individual isolates are to each other in their genetic 
makeover.  
The method generally involves the delicate preparation of unbroken purified chromosomal DNA, 
followed by restriction with a 6 bp recognition site endonuclease, and by separation in agarose gels that 
can resolve the resulting large fragments. In order to preserve the integrity and length of the specific DNA 
fragments, a culture of each isolate was mixed with low gelling-temperature agarose and fixed before 
undergoing lysis, washing, and endonuclease restriction (in our case we used SmaI). The small agarose 
disks were inserted in the wells of agarose gels and subjected to Pulsed-Field Gel Electrophoresis (PFGE). 
DNA fragments were identified with Ethidium Bromide and photographed under UV light. 
This electrophoretic method is a modification of the traditional gel electrophoresis, where the 
nucleic acids are subjected to an electric field and migrate towards the positive electrode; in PFGE the 
direction of the field sequentially alternates between two diagonal axes, inducing the large fragments of 
nucleic acid to be redirected alternately to the left and to the right of the main direction, and thereby 
creating a condition where every time the field changes the molecules need to readjust themselves to 
migrate along the agarose pores. The ability to quickly readjust and start migrating in a different direction 
is inversely correlated with the size of the molecule, resulting in the discrete separation of large nucleic 
acid fragments (40-400 kb) that would not be resolved in traditional electrophoresis.  
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3. Analysis of Serotype 6B Isolates from Iceland  
3.1. Background  
The work on S. pneumoniae described here was performed in 1992 in the laboratory of Dr. 
Alexander Tomasz at the Rockefeller University in New York. 
By the early 1990s, penicillin resistance and MDR pneumococci had emerged in large numbers and 
at numerous global locations [37]. Some of the work done at the time consisted in developing molecular 
and genomic based techniques for identifying and typing isolates, and in using them to identify clone 
migration.  
When my work took place in 1992, our collaborators in Iceland were alarmed by the quick spread 
of penicillin-resistance pneumococci. While sensitive isolates had been consistently collected since 1983, 
none had been identified with resistance to penicillin until 1988, at which point resistant isolates begun 
to appear, and rapidly climbed, reaching an incidence of 35 penicillin-resistant strains (more than 25 of 
them multi-resistant) on the last quarter of 1991. Since there was a predominance of isolates from 
serotype 6, and the policy for antibiotic use in the general population in Iceland was fairly restrictive, our 
colleagues postulated that the serotype 6 multi-resistant clone had been introduced from abroad - its 
spread facilitated by the grouping of children at day-care centers and by the more frequent use of 
antibiotics in children of that age [38].  
Our team collaborated with Dr. James Musser (Baylor College of Medicine, Houston, Texas), and 
Dr. Karl Kristinsson (National University Hospital in Reykjavik, Iceland) in comparing these isolates to 
collections of other isolates of serotype 6B from Spain, Alaska, and Texas using molecular-based typing 
methods. 
3.2. Experiments and results 
Fifty-seven (57) clinical isolates of S. pneumoniae were obtained from the collection of the National 
Hospital in Reykjavik, representing isolates from Iceland collected from 1989 to 1991. The isolates 
belonged to serotype 6B, showing virtually identical multi-resistant phenotypes and, as described above, 
suggesting an epidemic spread of a single bacterial clone.  These isolates were studied and compared 
with a subgroup of multiresistant serotype 6B pneumococci with high incidence in Spain in the prior two 
decades. Additional pneumococcal serotype 6B isolates from Alaska, Texas and England were used as 
controls in specific studies, as well as occasional isolates of different serotypes and different clones (as 
indicated in specific experiments). 
Penicillin resistance was initially screened by disk diffusion, plating cultures of each isolate on 
Oxoid agar plates with 1μg oxacillin and 6% horse blood. Oxacillin, a β-lactam antibiotic of the same class 
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as penicillin, was first described by Dixon et al. in 1977 [39], for use in disk diffusion for screening strains 
of S. pneumoniae as penicillin disks did not reliably detect all resistant strains. Penicillin susceptible 
strains of pneumococci reliably produce oxacillin zones of 20 mm or greater, but oxacillin zones of ≤ 19 
mm can be obtained with resistant, intermediate and with some penicillin-susceptible strains. MICs 
(Minimum Inhibitory Concentrations) were then determined by agar dilutions for strains with zone 
diameters of ≤ 19 mm.  
Variations of 15 enzyme loci were assessed by Multilocus Enzyme Electrophoresis by the team in 
the laboratory of Dr. James Musser, Baylor College of Medicine, Houston, Texas. Extracts of cultures were 
run through multiple protein separation gels and each assayed for enzymatic activity detected with a 
labeled dye. Photographs of the protein gels were analyzed, and each variable mobility pattern for each 
enzyme locus was assigned an allele type. The allele type for each collection of isolates is represented in 
Table 1.1 with a number, in summarized format due to the large extension of data.  The combination of 
the same alleles over the 15 enzyme loci was assigned a specific Electrophoretic Type (ET), represented 
in Table 1.1 by a letter on the right-most column.  
 
Table 1.1. Multilocus Enzyme Electrophoresis Allele Types of Isolates by Origin 
Numbers in the “Isolate Origin” column indicate the number of isolates that display the allele type indicated 
on the table over the total number of isolates on the collection. Allele types were arbitrarily assigned a number. 
For easier visualization of the differences, when a collection of isolates displays a different allele type than the 
others, that allele type is shown in blue font. Enzyme loci: (NSP) nucleoside phosphorylase, (LAP) leucine 
aminopeptidase, (ADK) adenylate kinase, (CAK) carbamylate kinase, (PGI) phosphoglucose isomerase, 
(EST1/EST2) esterase 1/2, (PGM) phosphoglucomutase, (LDH) lactate dehydrogenase, (GP1/GP2) glucose-6-
phosphate dehydrogenase 1/2, (6PG) 6-phosphogluconate dehydrogenase, (G3P) glyceraldehyde-3-phosphate 
dehydrogenase, (GLD) glutamate dehydrogenase, (ADH) alcohol dehydrogenase. (ET) Electrophoretic Type, 
assigned according to the pattern of allele types at all the enzyme loci. The individual results for each isolate 






The results show that 56 of the 57 Icelandic isolates showed the same ET in all 15 enzyme loci 
assayed, and they were indistinguishable from 11 of the 12 isolates from Spain. The one Icelandic isolate 











Allele Type at each Enzyme Locus
ET
3 5 5 5 5 5 5 5 5 A
3 5 5 5 5 5 5
5 5 5 3 5 5
5 5 A
5 5 5 5 5 5 5
5 5 5 3 5 5
3 5 E
3 7 5 5 5 5 3
5 5 5 5 5 5
5 5 F3 3 5 3 8 5
Analysis of Serotype 6B Isolates from Iceland 
 11 
that was different (IC45), differed from the others in a single enzyme locus, EST2. The Alaska and Texas 
isolates differed more extensively from the Spanish-Icelandic ET at 2 to 5 enzyme loci. These results show 
that most of the isolates from Iceland have the same enzyme electrophoretic profile as the majority of 
the isolates from Spain, and differ from other serotype 6B isolates collected in Texas and Alaska, 
substantiating the hypothesis of a single origin between the Icelandic and Spanish isolates. 
PBP patterns were assayed as described in section 2.2. As a reference, a penicillin susceptible non-
encapsulated laboratory strain with a documented PBP pattern was used (R36A). In addition, a 
representative of a different clone also from Spain was included. Results are summarized in Figure 1.5, 
and the PBP pattern observed for each isolate is summarized in Table 1.2 (page 15). 
 
 
Figure 1.5. PBP (Penicillin Binding Protein) profiles of multiresistant isolates 
IC: Iceland, Ala: Alaska, S: Susceptible Strain R36A. Arrow: control isolate from different clone from Spain. 
It should be noted that PBP 2x is not resolved from 2A as was frequently the case in protein gels at the time 
of this work [40]. 
 
PBP 2X appears unresolved from PBP 2A, as it typically did in protein gels at the time this work was 
performed; in fact, reference to PBP 2X is largely inconsistent in literature of the late 1980s and early 
1990s [40,41].  
The results show that the PBP profile is common among all 57 Icelandic isolates, and identical to 
the 6B isolates from Spain, but distinct from the Alaskan isolates and the control susceptible strain. The 
arrow indicates a Spanish isolate known to be from a different clone, which also shows a distinct pattern. 
The PBPs 1B and 2A of Icelandic and Spanish isolates show somewhat reduced affinity for penicillin, 
as reflected by the reduced intensity of the bands in the autoradiograph. Additionally, PBPs 1A and 2B of 
those isolates are either fully altered or have negligible affinity for penicillin, in a way that they are not 
visible in the autoradiograph. These reduced penicillin-affinities or altered proteins are likely the cause 
for the low-level penicillin resistance observed in these isolates; in fact, PBPs 1A, 2B and 2X (the latter 
one being unresolved as previously mentioned) have been identified as the main players in resistance to 
penicillin, and mutations in PBP 2X and/or PBP 2B have been shown to result in low-level resistance to 
penicillin [42,43]. 
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We subjected the chromosomal DNA of the pneumococcal isolates to endonuclease restriction 
with SmaI and to PFGE as described in section 2.3, and the results are shown in Figure 1.6, Figure 1.7 and 
Figure 1.8. Unfortunately, not all photographs of PFGE gels have transferred well to electronic form and 
some differences are difficult to visualize. Each individual PFGE pattern was assigned a Greek letter and 
the pattern exhibited by each isolate is summarized in Table 1.2 (page 15). 
 
 
Figure 1.6. PFGE patterns of the SmaI fragmented chromosomal DNA 
(IC) Icelandic isolates; (Spain) Spanish isolates; (Tx) Texas isolates; (λ) Molecular size markers λ ladder and 
low-range PFG (New England Biolabs, Beverly, MA), size indicated in kb. Most Iceland and Spanish isolates 
display an identical pattern arbitrarily named α, or different patterns that are closely related to α. All the 
isolates showing a pattern different than α are marked with their isolate number and the arrowhead 
indicates a strain of penicillin-resistant pneumococcus of a different clone. The pattern displayed by each 
isolate is summarized in Table 1.2 (page 15). 
  





Figure 1.7. Prevalent PFGE SmaI pattern in isolates 
from Iceland, Spain, and England 
Serotype 6B isolates from Spain and Iceland were 
compared with other serotype 6B isolates from 
England from the Rockefeller University collection, 
showing the common pattern α, with minor 
variations in two England isolates. A multi-resistant 
isolate of serotype 23F from Spain (marked with 
arrowhead), belonging to a different clone studied 
by Muñoz et al. [33,44], is included for contrast. 
Figure 1.8. Different PFGE SmaI patterns of various 
isolates.  
(1,2) Tex224 and Tex275, multi-resistant isolates from 
Texas, showing pattern θ (theta) with minor variations, 
θ1 and θ2. (3) Most common Icelandic isolate pattern 
α (alpha) represented by IC10. (4) Icelandic isolate IC45 
showing pattern γ (gamma). (5,6) Spanish isolates 
Md970 and Md114 showing patterns σ (sigma) and δ 
(delta), respectively. (7-12) Penicillin-susceptible 
serotype 6B isolates collected in Iceland from January 
1990 to March 1992, showing multiple patterns, and 
different from the most common resistant pattern. 
 
The PFGE results show a common pattern in 54 out of the 57 studied isolates, arbitrarily named α, 
with seven discrete DNA fragments between approx. 90 kb and 388 kb, and only minor differences shown 
by the remaining three isolates (Figure 1.6 and Figure 1.7). The set of DNA fragments smaller than 97 kb 
are below the resolution threshold for the PFGE method used; they show non-discrete bands indicating 
multiple fragments without clear separation and are not consistently resolved in all gels; therefore, they 
were not considered when analyzing results in this study. 
Isolate IC45 (Figure 1.6 and Figure 1.8), when compared to the most common pattern, is missing a 
band at approximate 194 kb and showing one extra band just above 145.5 kb (clearly visible by comparing 
lanes 3 and 4 of Figure 1.8). This could be the result of a deletion, or a single point mutation creating a 
new SmaI restriction site within the 194 kb fragment, therefore breaking it in two: a fragment of 
approximately 150 kb and a smaller fragment in the neighborhood of 44 kb which would not be clearly 
visible due to its small size.   
Isolates IC23 (Figure 1.6, upper middle panel) and IC59 (data not shown, but summarized in Table 
1.2, page 15) showed and even smaller difference from the most common pattern, displaying a very faint 
band just below the 339.5 kb marker. The pattern, named β1 or β2, is common between these and three 
isolates from Spain, Md656, Sp668 and Sp681 (Figure 1.6, lower right panel). Pattern β2 displayed by 
Sp668 and Sp681 shows a slightly more intense band just below the 339.5 kb marker than pattern β1 
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shared between Md656 and IC23, although difficult to visualize in the figures for IC23. It may be that this 
is just a visual artifact. However, these small differences do not detract from the main point that both β1 
and β2 patterns are almost identical to the most common pattern α, found in most isolates studied.  
Interestingly, two serotype 6B isolates from England, drawn from the Rockefeller University 
collection for comparison in PFGE, but that were not fully part of this study, also show an α-like pattern, 
matching the common Icelandic and Spanish isolates with only a slightly smaller fragment just above the 
194 kb marker. This could be the result of a single deletion without impacting SmaI restriction sites. 
It is also relevant to point out that PFGE clearly identifies the genomic variety presented by other 
S. pneumoniae isolates, which is apparent in Figure 1.8. 
 
3.3. Summary and analysis 
This work started with the hypothesis that the surge of multi-resistant pneumococcal isolates 
collected in Iceland from 1988 to 1991 originated from a single clone. The 57 isolates of serotype 6B 
chosen for this study were analyzed by three molecular typing techniques: PBP patterns by SDS-PAGE, 
Multiloccus Enzyme Electrophoresis, and PFGE. The Icelandic isolates were compared with 12 isolates 
from Spain with similar phenotypic characteristics that had a high incidence in Spain a few years before 
the Iceland spike started. For controls, serotype 6B strains from two different geographic areas in the US 
were used (Texas and Alaska).  
All results collected in this study are listed in Table 1.2 (page 15), in conjunction with 
epidemiologically relevant Information and antibiotic susceptibility of the isolates. Gel patterns were 
arbitrarily assigned letters to designate identical or different patterns, with an extra asterisk or a subset 
1 or 2, assigned to indicate only a minor difference. 
MIC results are also presented in Table 1.2 and show MICs for penicillin between 0.5 and 2 μg/ml, 
levels that are not very different among the isolates, and which classify at low levels of resistance 
according to the literature available at the time [37,45]. It may be interesting to note that according later 
classifications, these MICs were grouped in the category of intermediate or borderline/below resistant 
[46,47],  perhaps representative of the continuing increase in the level and prevalence of resistance, 
which is widely mentioned in the literature since the 1980s and was carefully studied in Tennessee during 
a 10-year period [48]. 
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Table 1.2. Epidemiological, phenotypical, and molecular properties of the isolates 
Type of Infection: (B) exacerbation of chronic bronchitis, (BL) septicemia, (C) carrier, not infected, (E) eye, conjunctivitis, 
(M) meningitis, (O) otitis media, (P) pneumonia, (S) sinusitis, (U) undefined. Antibiotic resistance: (S) susceptible, (I) 
intermediate, (R) resistant. (-) Not determined or not known. Multilocus enzyme electrophoretic types of Spanish Sp 
isolates were determined in B. Spratt's laboratory (Brighton, UK). Isolates showing small differences from the most common 














PFGE Sma I 
Pattern
IC2 1991.09 1 O 6B R I I 1 a A α
IC3 1991.09 3 C 6B R I I 1 a A α
IC4 1991.09 29 P 6B R R I 1 a A α
IC5 1991.09 1 S 6B R R I 1 a A α
IC6 1991.08 17 P 6B R R R 0.5 a A α
IC7 1991.07 2 O 6B R R R 1 a A α
IC8 1991.07 69 B 6B R R R 0.5 a A α
IC9 1991.07 85 P 6B R I R 1 a A α
IC10 1991.06 (8) O 6B R I I 1 a A α
IC11 1991.06 (10) O 6B R R R 1 a A α
IC12 1991.05 1 U 6B R R R 0.5 a A α
IC13 1991.05 (4) C 6B R R I 0.5 a A α
IC14 1991.05 2 U 6B R I I 1 a A α
IC15 1991.05 2 U 6B R I I 1 a A α
IC17 1991.04 (11) O 6B R R R 2 a A α
IC18 1991.04 18 U 6B R R R 1 a A α
IC19 1991.04 1 O 6B R R I 2 a A α
IC20 1991.04 1 O 6B R R I 2 a A α
IC21 1991.04 1 U 6B R R I 1 a A α
IC22 1991.03 1 O 6B R R I 1 a A α
IC23 1991.03 1 S 6B R R R 2 a A β1
IC24 1991.03 73 P 6B R R R 1 a A α
IC25 1991.03 1 BL 6B R R R 1 a A α
IC26 1991.03 (6) O 6B R R R 1 a A α
IC27 1991.03 1 O 6B R I I 1 a A α
IC28 1991.03 1 O 6B R R R 1 a A α
IC29 1991.03 (9) O 6B R R R 2 a A α
IC30 1991.03 1 O 6B R R R 1 a A α
IC31 1991.02 28 S 6B R R R 1 a A α
IC32 1991.02 28 U 6B R R R 1 a A α
IC33 1991.02 31 U 6B R R I 1 a A α
IC34 1991.02 (11) O 6B R R R 2 a A α
IC35 1991.01 (1) U 6B R I I 1 a A α
IC36 1991.01 1 O 6B R R I 1 a A α
IC37 1991.01 3 U 6B R R R 1 a A α
IC38 1990.12 67 P 6B R R I 1 a A α
IC39 1990.10 (10) O 6B R R I 1 a A α
IC40 1990.11 71 P 6B R R I 1 a A α
IC41 1990.10 2 O 6B R I I 2 a A α
IC42 1990.09 79 P 6B R R I 1 a A α
IC43 1990.08 1 O 6B R R R 1 a A α
IC44 1990.08 (4) O 6B R R R 1 a A α
IC45 1990.06 3 U 6B R S R 1 a A* γ
IC46 1990.05 89 S 6B R R R 1 a A α
IC48 1990.04 72 P 6B R R R 0.5 a A α
IC49 1990.02 33 S 6B R R R 0.5 a A α
IC50 1990.01 12 O 6B R R S 0.5 a A α
IC51 1990.01 (11) O 6B R I R 1 a A α
IC52 1989.12 4 O 6B R R R 0.5 a A α
IC53 1989.11 1 U 6B R R I 0.5 a A α
IC54 1989.08 40 B 6B R R I 0.5 a A α
IC55 1989.08 1 O 6B R R R 0.5 a A α
IC56 1989.06 (10) U 6B R R I 1 a A α
IC57 1989.05 1 O 6B - R - 2 a A α
IC58 1989.05 2 O 6B - R - 2 a A α
IC59 1989.04 (6) O 6B - R I 2 a A β1
IC60 1991.09 2 E 6B R R R 0.5 a A α
Sp522 1987-89 - - 6B - - - 2 a A α
Md873 1987-89 - - 6B R S R 2 a A α
Md2067 1987-89 - - 6B R S R 2 a A** α
Md1238 1987-89 - - 6B R R R 2 a A α
Sp647 1987-89 - - 6B - - - 2 a A α*
Sp652 1987-89 - - 6B - - - 2 a A α*
Md656 1987-89 - - 6B R S R 2 a A β1
Sp668 1987-89 - - 6B - - - 2 a A β2
Sp681 1987-89 - - 6B - - - 2 a A β2
Md1625 1987-89 - - 6B R S R 2 a A δ
Md114 1987-89 - - 6B R S R 2 a A δ
Md970 1987-89 - - 6B R S R 2 a A σ
Tex224 1989-91 - - 6B S I S 4 a* F θ1
Tex275 1989-91 - - 6B S S S 4 a* F θ2
Ala1 1982.03 1 P 6B S S S 0.1 e E φ
Ala15 1986.05 1 P 6B S S S 0.3 e E φ
Ala31 1988.07 (10) - 6B S I S 0.1 e E φ*
Ala39 1989.06 (2) M 6B S R S 0.3 e E φ*
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Our results show that 95% of the Iceland isolates (54/57) show identical patterns in all three 
molecular typing techniques. Those patterns are shared with 50% of the isolates from Spain (6/12), with 
minor variants excluded. This evidence supports the hypothesis that most Icelandic isolates originated 
from a single clone, and that that clone was imported, potentially from Spain. The findings in the England 
isolates, which show similar PFGE patterns in Figure 1.7, point to a perhaps wider spread of the initial 
clone. In contrast, the different patterns of several isolates from Spain, Texas, and Alaska show that the 
techniques can differentiate clones of pneumococci from one another.  
It is especially noteworthy that PFGE, an innovative technique at the time, was able to provide a 
large variety of patterns for the isolates studied and differentiate clones from Spain that would otherwise 
look identical. PBP and Multilocus Enzyme Electrophoresis both highlight protein differences that impact 
protein gel mobility and ability to bind substrate. However, PFGE highlights genomic sequence differences 
at the DNA level, i.e., mutations or chromosomal rearrangements. Many of those can be completely silent 
(not impacting translation), or they may impact protein sequence but not mobility or substrate affinity, 
or they may also have a significant impact in the structure and function of proteins that are not penicillin-
binding, or one of the 15 enzymes selected for Multilocus Enzyme Electrophoresis - in all cases providing 
possible explanations for the increased discernment of the genomic method.  PFGE was one of the first 
genomic methods used for identification and typing in the early 1990s, leading the way to more 
sophisticated genomic and mutation analysis techniques which are mentioned later (6.2. Evolution of 
typing techniques). 
This work was published in 1993 in the Journal of Infectious Diseases with the title “Evidence for 
the Introduction of a Multiresistant Clone of Serotype 6B S. pneumoniae from Spain to Iceland in the Late 
1980s” [49]. 
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4. Serotype 23F Isolates from North Carolina 
4.1. Background 
My work with molecular typing, especially PFGE, also helped provide evidence for a study of 
Serotype 23F pneumococci from North Carolina, USA, where a clonal outbreak was suspected. Children 
from a day care center in Chapel Hill, North Carolina were under surveillance for nasopharyngeal 
colonization with S. pneumoniae since 1985. In May 1990, an outbreak started, where nasal carriage of 
MDR resistant serotype 23F was observed in multiple isolates sampled from 14 out of 52 children until 
December 1991.  
Muñoz et al. and Reichler et al. [33,50] had reported a similar outbreak in a Cleveland, Ohio 
daycare. Muñoz et al.  compared it to a collection of Spanish serotype 23F pneumococcus isolates for PBP 
mobility as well as penicillin binding capacity through PBP autoradiograph patterns, broad enzymatic 
uniformity through multilocus enzyme electrophoresis, and additionally used a PCR based gene 
fingerprinting technique to analyze the DNA sequence of PBPs through restriction mapping. They 
concluded that the isolates collected in Spain in 1989 (where multi-drug resistance had been observed in 
the prior 5-10 years) were of the same clonal origin as those collected in the Cleveland daycare, likely 
moving from Spain to Cleveland, Ohio [33]. 
The body of work reviewed below consisted of using traditional and molecular typing techniques 
to investigate the correlation of the Chapel Hill isolates to the Cleveland and Spain isolates reported by 
Muñoz et al. [33]. 
4.2. Experiments and results 
A total of 1123 S. pneumoniae isolates were collected during the surveillance program in Chapel 
Hill, with 207 being selected for antibiotic susceptibility testing, each representing a colonization episode 
of a certain serotype. Serotype 23F was prevalent during 1990 and 1991. A total of 13 MDR and 10 
penicillin-susceptible (PS) serotype 23F isolates collected at the time of the North Carolina daycare 
outbreak were selected for further studies of molecular nature (PBP and PFGE) and compared with 
several other isolates from Spain, Ohio and Texas. 
PBP and PFGE studies were executed as described previously in Section 2. PBP results are shown in 
Figure 1.9 and Figure 1.10; PFGE results are shown in Figure 1.11 and Figure 1.12 . 
 
Chapter 1. Molecular Typing of Multi-drug Resistant Streptococcus pneumoniae 
 18 
 
Figure 1.9. PBP pattern of MDR serotype 23F isolates 
(NC 1-13) MDR isolates from Chapel Hill, North Carolina. (Ohio 1-3) MDR isolates from Cleveland, Ohio reported 
by Muñoz et al. and Reichler et al. [33,50]. (R6) Laboratory standard penicillin-susceptible strain R6. Both 
collections of isolates show an identical pattern (with only the exception of isolate NC13), with alterations in 
penicillin-binding proteins 1A and 2B. As previously mentioned, PBP 2X appears unresolved from PBP 2A. 
 
 
Figure 1.10. PBP pattern of Penicillin-Susceptible isolates 
(NC 14-24) PS serotype 23F isolates from Chapel Hill, North Carolina. (14 S-R) Serotype 14 isolates from Chapel 
Hill daycare collected from the same child about four months apart; S: penicillin-susceptible, R: MDR. (NC 28-29) 
Serotype 23F isolates from Chapel Hill; 28: penicillin-susceptible, 29: MDR. (TX 1-2) MDR Serotype 6B isolates 
from Texas.  (R6) Laboratory standard penicillin-susceptible strain R6. Penicillin susceptible isolates display PBP 
patterns similar to the control strain R6 (with perhaps only slight mobility-affecting alterations in PBP 1B or 2B). 
In contrast, MDR isolates 14R, NC29, TX1 and TX2 of serotypes 14, 23F and 6B, respectively, show PBP patterns 
with significant alterations in proteins 1A and 2B. Although this pattern is similar across the three serotypes, 
some differences can be seen, namely in the PBP 1B band and the intensity of the PBP 2A band. As previously 
mentioned, PBP 2X appears unresolved from PBP 2A. 
 
The PBP autoradiographs show a common pattern, arbitrarily named a, between the NC 1-12 MDR 
isolates of serotype 23F from North Carolina and Ohio, displaying significantly altered PBPs 1A and 2B 
(Figure 1.9). Isolate NC13 shows a slightly different pattern arbitrarily named a*. These patterns a and a* 
are also displayed by other MDR isolates, namely, 14R, NC29 and two isolates of serotype 14 from Texas, 
Tx 1-2 (Figure 1.10). Penicillin-susceptible isolates show a pattern named b that is common with the 
reference susceptible strain R6 (Figure 1.10). Results are summarized in Table 1.3 (page 20). 
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Figure 1.11. PFGE of MDR serotype 23F isolates 
(NC 1-12) MDR serotype 23F isolates from Chapel Hill, North Carolina. (λ) Molecular size 
markers λ ladder and low-range PFG (New England Biolabs, Beverly, MA), size indicated in kb. 
 
Figure 1.12. PFGE of various isolates 
(NC 24-25) Penicillin susceptible serotype 23F isolates from Chapel Hill. NC24’s pattern cannot 
be assessed due to degradation. (NC 7-12) MDR serotype 23F isolates from Chapel Hill. (Spain, 
Ohio) MDR serotype 23F isolates from Spain and Ohio, respectively.  (14 S-R) Serotype 14 isolates 
from Chapel Hill daycare collected sequentially from the same child; S: penicillin-susceptible, R: 
MDR. (NC 28-29) Serotype 23F isolates from Chapel Hill; 28: penicillin-susceptible, 29: MDR. 
 
PFGE results also show a prevalence of two remarkably similar patterns in the North Carolina MDR 
isolates (Figure 1.11); the pattern arbitrarily named A1 is common between isolates NC 1-10 and identical 
to the Ohio isolates. Pattern A2 is displayed by isolates NC11 and NC12 and differs from A1 only in the 
194-242 kb range. The Spanish isolates also show patterns extraordinarily like A1 and A2 with only one 
band slightly shifted in the 145 kb area (Figure 1.12). Results are summarized in Table 1.3.  
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Table 1.3. Summary of Serotype 23F isolates and PBP/PFGE patterns 
(MDR) Multidrug Resistant; (MDR*) Multidrug Resistant but susceptible to Erythromycin. PS: Penicillin 
Susceptible. (-) Not available. PBP and PFGE patterns can be found in Figures 1.9 to 1.12, and explanation is 




A few point-mutations could be all that is different between these MDR isolates, supporting the 
hypothesis that they originated from a single S. pneumoniae serotype 23F MDR clone that spread across 
continents from Spain to at least two areas of the United States. A few other PFGE patterns can be 
observed in individual North Carolina isolates NC25, NC28 (both penicillin-susceptible) and NC29 (MDR) 
that are not shared with any others, indicating there are other, perhaps less prevalent, clones in the 
population. 
Although the molecular data from these techniques indicate with reasonable certainty that the 
isolates from North Carolina originate from the same clone as the isolates from Spain and Cleveland, 
there is a relevant difference that should be mentioned. The isolates from Spain and Cleveland were 
multidrug resistant but susceptible to Erythromycin, whereas the isolates from Chapel Hill were highly 
resistant to Erythromycin. Since the Chapel Hill day care surveillance program shows that the last 
Erythromycin resistant isolate occurred 12 years prior to the MDR 23F outbreak, it is unlikely that 
resistance was acquired upon arrival in North Carolina; therefore, it is postulated that this clone was 
introduced into North Carolina through at least one intermediary location, where it would have acquired 
Erythromycin resistance, and not directly from Cleveland or Spain. 
It should be pointed out that although side-by-side comparisons are not available, the PBP pattern 
of the MDR serotype 23F isolates (Figure 1.9) is very similar to that of the 6B isolates from Iceland 
reported in Figure 1.5; however the PFGE patterns are quite different between these two collections of 
isolates (Figure 1.6 and Figure 1.11), confirming earlier conclusions that PFGE provides higher 
discriminatory power than the PBP pattern in differentiating strains. 







PBP pattern PFGE 
pattern 
NC 1-13 Chapel Hill, 
NC 
1990-91 13 23F MDR a, a* A1, A2 
NC 14-24 Chapel Hill, 
NC 
1990-91 10 23F PS b - 
NC 25 Chapel Hill, 
NC 
1990-91 1 23F PS - B 
NC 28 Chapel Hill, 
NC 
1990-91 1 23F PS b C 
NC 29 Chapel Hill, 
NC 
1990-91 1 23F MDR a* D 
Ohio 1-3 Cleveland,  
OH 




Spain 1989 2 23F MDR* - A1*, A2* 
Tx 1-2 
 
Texas - 2 6B MDR a - 
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4.3. Case-study: hypothesized seroconversion 
An interesting hypothesis can be derived from the analysis of a subset of the data presented above. 
My colleagues studying the serotype and drug resistant patterns of the isolates from the Chapel Hill 
daycare had noticed that one specific child was colonized with MDR serotype 23F at two sequential time-
points: November 1990 and January 1991. That child became colonized with penicillin-susceptible (PS) 
serotype 14 in February 1991 and then with MDR serotype 14 in June of the same year. A schematic 
timeline of isolate collection from the child is presented in Figure 1.13. 




Figure 1.13. Schematic timeline of isolate collection from a specific child in the North Carolina daycare 
Time points and isolate characteristics are described in the text. (MDR) Multi Drug Resistant. (PS) Penicillin 
Susceptible. (23F) Serotype 23F. (14) Serotype 14. 
 
Table 1.4. Summary of isolates collected from the same child 
Antibiotic Resistance: (R) Multidrug Resistant. (S) Penicillin Susceptible. PBP Patterns: (a) most common pattern 
found in MDR serotype 23F isolates. (b*) pattern similar to frequent susceptible pattern b, found in susceptible 
isolates NC14-24 and in reference strain R6. PFGE Patterns: (A1) Most common pattern found in MDR serotype 








(Figure 1.9 and Figure 1.10) 
PFGE Pattern 
(Figure 1.11 and Figure 1.12) 
Isolate No. Pattern Isolate No. Pattern 
1990 Nov 23F R 
NC 1 - 12 
NC 29 
a 
NC 1 - 12 
NC 29 
A1/A2 
1991 Jan 23F R 
NC 1 - 12 
NC 29 
a 
NC 1 - 12 
NC 29 
A1/A2 
1991 Feb 14 S 14S b* 14S E 
1991 Jun 14 R 14R a 14R A3 
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As expected, the patterns of the penicillin susceptible isolate 14S are different from the MDR 23F 
patterns. However, the subsequently emerged isolate 14R, collected from the same child, shows PBP and 
PFGE patterns that are remarkably like the most common MDR 23F patterns, which had also been isolated 
from the same child. This finding leads us to the hypothesis that maybe, instead of undergoing antibiotic 
resistance conversion from susceptible to resistant, the child might have harbored both serotypes and 
enabled an exchange in capsular coding material from the new serotype 14 into the original MDR 
serotype 23F, in such a way that the MDR serotype 23F converted to serotype 14. Capsular switching or 
serotype conversion is a well described phenomenon in S. pneumoniae literature [25] as highlighted in 
the introduction to this chapter. However, we do not have enough data to confirm this hypothesis. 
This work was published in 1995 in the Journal of Infectious Diseases with the title “Transmission 
of Multidrug-Resistant Serotype 23F S. pneumoniae in Group Day Care: Evidence Suggesting Capsular 




The findings from the molecular typing work described above support the hypothesis that 
multidrug resistant clones of S. pneumoniae were transferred across borders and propagated in child day 
care centers. 
With respect to the clone of serotype 6B, the conclusions may be summarized as follows: a) 95% 
of the Iceland isolates show identical patterns and match 50% of the isolates from Spain, with minor 
variants excluded; b) evidence supports the hypothesis that most Icelandic isolates originated from a 
single clone; and c) since the clone had been established in Spain for 3 decades and no resistant isolates 
were found in Iceland until 3 years prior, it is likely that the clone was imported from Spain.  
As to the clone of serotype 23F: a) all the North Carolina isolates share two extremely similar 
patterns, which match the Ohio and Spain isolates; b) evidence supports that the isolates from North 
Carolina originated from the same clone as the isolates from Spain and Cleveland, and it is likely that the 
clone was propagated from Spain, since multidrug resistance was prevalent in Spain for decades prior, 
but not in the Unites States; and c) it is postulated that this clone was introduced into North Carolina 
through at least one intermediary location, where it would have acquired Erythromycin resistance, 
because resistance to this antibiotic had not observed in Chapel Hill in the prior 12 years.  
The molecular typing of S. pneumoniae isolates that I performed was important at a time when the 
travel of clones across borders was just beginning to be suspected. PFGE was not a prevalent technique 
at the time, and with my work, I was able to provide reasonable evidence that the travel of multidrug 
resistant clones from Spain was the most likely reason for the appearance of the 6B clone in Iceland, and 
that the 23F clone from Spain and Ohio had made it to North Carolina. 
The emergence of antibiotic resistance was just beginning to be raised as a problem. From both 
the analysis of the 6B clone and the 23F clone, there was evidence that children in day care centers were 
passing on these resistant bacteria and propagating the problem. It was important to raise awareness to 
the fact that the random and frequent use of antibiotics needed to be reduced – or pathogenic bacteria 
like S. pneumoniae could evolve into full drug resistance at a faster rate than new drugs could be 
discovered.  This battle is by no means over, but today there is a higher level of awareness and increased 
restraint in the use of antibiotics, by both doctors and patients, than in the early 90s.  
PFGE, the technique that I inherited and fine-tuned in Dr. Tomasz’s lab continued to be improved 
and used in epidemiologic work; it is referred today as a “historically important molecular method” [25]. 
The two clones that I studied went on establish formal pneumococcus lineages and were found in 
other areas beyond the places that I identified (see section 6.1). 
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6. Further Developments 
6.1. Changes in pneumococcal epidemiology 
During their work on the development of a then novel molecular method for pneumococcus 
epidemiological studies, Multi-Locus Sequence Typing (MLST), in 1998, Enright and Spratt included a few 
samples of the serotype 6B and serotype 23F clones from Spain that I reported in sections 3 and 4, 
respectively. In their publication they verified with the new technique that each of them likely originated 
from a single clone and used the data to validate their new method [52].  
Aiming at global surveillance of antibiotic-resistant pneumococcus, the Pneumococcal Molecular 
Epidemiology Network (PMEN) [53] was established in 1997. It brought standardization and structure to 
the field of S. pneumoniae epidemiology, with consistent nomenclature and classification of clones.  As 
of May 2020, there were 43 clones/lineages listed by the PMEN. In the initial release of the clone 
classification by McGee et al. in their 2001 publication, the 23F clone that I reported in section 4 
established the PMEN1 lineage. The PMEN2 lineage was established by the serotype 6B clone reported 
in section 3 [47].  
PMEN1, also referred to as the 23F Spanish/USA clone or Spain23F-1,  was identified and studied in 
numerous publications as having been ubiquitous around the globe for decades; it is typically 
characterized as a low virulence, multi-drug resistant, highly pervasive clone in non-symptomatic carriers 
[47,54,55]. 
However, many studies have found that the prevalence of capsular serotypes has shifted after the 
1990s for several reasons.  
The prevalence of PMEN2, also referred to as or Spain6B-2, the 6B clone prevalent in Iceland 
reported in section 3, remained the predominant type among penicillin-resistant S. pneumoniae through 
1996 [56], but declined in Iceland after the mid-1990s [54]. Croucher et al. published a study in 2014 with 
Whole Genome Sequencing analysis of 189 isolates from 12 countries, including 118 from Iceland, 
collected from the late 1980s to 2009, where they observed that the Icelandic clade of PMEN2 lost 
antibiotic resistance over time, and lacked the importation of divergent sequences through homologous 
recombination when compared to other clades of PMEN2 outside Iceland. The decreased selective 
pressure for multi-drug resistance, achieved by the country’s reduction of antibiotic administration to 
children after 1992, as well as the clone’s lack of antigenic diversification resulting from the absence of 
recombination, might have contributed to the decline [54]. 
Since the widespread implementation of the Pneumococcal Conjugate Vaccines (PCV7 in 2000 and 
subsequently PCV13 in 2010, which contain polysaccharide antigens for a total of 7 and 13 serotypes 
respectively), Invasive Pneumococcal Disease (IPD) has significantly decreased. However, S. pneumoniae 
continues to be recovered, frequently from vaccinated children, and the bacterial population has shown 
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changes. There is multiple evidence of genomic recombination and cases of serotype switches 
[2,55,57,58]. Interestingly though, serotype replacement occurs mainly due to expansion of non-vaccine 
types that pre-existed before vaccine introduction; postvaccine capsular switches (from vaccine types to 
non-vaccine types) did not contribute significantly to the pool of post-vaccine drug resistant isolates [59].  
As of May 2020, two new and expanded pneumococcal conjugate vaccines are already on the 
horizon. PCV15 is in Phase 3 (last stage) clinical trials, with completion expected in May 2021 [60], and 
PCV20 is in early development. It will be interesting to observe the evolution of the pneumococcal 
population if these vaccines become widely administered to children, replacing PCV13. 
6.2. Evolution of typing techniques 
My work on S. pneumoniae was performed during a time when molecular techniques of analysis 
were beginning to be explored for studies of microbial diversity and general epidemiology. Even though 
the techniques presented here have limited efficacy and very low throughput, they are the base for a set 
of methods that started brewing at the time and succeeded later with lower costs and higher efficiencies, 
culminating with genomic sequencing and real-time PCR today.  
In the paragraphs below is a modest overview of the evolution of techniques related to my work 
after its execution in the early 1990s. This does not aim to be a complete scholarly review, but instead to 
assess how techniques evolved from each other, how they advanced, and how they impacted the field of 
pneumococcus epidemiology and the science of today. 
PFGE continued to be used and was a historically important method of characterization for many 
microorganisms [25].  It was further validated and standardized for wider use across laboratories with 
guidelines released in 1995 [61,62].  It is interesting to observe that with wider use and standardized 
guidelines, the quality of PFGE gels increased remarkably over time, with improved resolution, increased 
visibility of discrete band patterns, and straighter gel lanes – features that my work did not consistently 
achieve at the time. 
The PFGE method is related to RFLP (Restriction Fragment Length Polymorphism), which was 
initially developed by Alec Jeffreys starting in the late 1970s and published in 1979 [63]; the original 
method involved digesting human chromosomal DNA with restriction enzymes, separating the resulting 
fragments by gel electrophoresis and detecting specific regions by Southern blot hybridization with 
radioactively labeled probes targeting various types of globin genes. It revealed that specific variants were 
associated with different individuals and was used to establish the link to maternal heritage [63]. This 
discovery unleashed several subsequent applications including forensics, paternity/twin testing, and 
conservation biology [64,65].  
The wide use of RFLPs was greatly limited by the need for large quantities of genomic DNA; 
however, this problem was solved in 1985 with the epic advent of the Polymerase Chain Reaction (PCR) 
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[66,67]. RFLP analysis was combined with PCR amplification, which resolved the large quantity problem 
and facilitated its wide use, for example as a diagnostic tool for sickle cell anemia [66].  
PCR is a well-established and extensively used technology that is based on the selective large-scale 
amplification of DNA fragments. DNA polymerases that withstand sequential denaturation at high 
temperatures are allowed repeated and cyclical access to single-stranded and primed DNA template, 
which they use to construct the complementary strand. The repeated cycles, and the ability to use the 
product of a previous cycle as the template for the next, provide for a logarithmic amplification power of 
select DNA fragments.  
PCR has a multitude of uses in Molecular Biology, and as it became widely accessible, it quickly 
started to be incorporated in S. pneumoniae typing methods. A few examples are mentioned below. 
In 1996, van Belkum [68] published results of a novel DNA fingerprinting technique, BOX-PCR, 
targeting a series of interspersed repetitive DNA sequences that are characteristic of S. pneumoniae [69], 
matching typing resolutions of prior techniques and increasing speed and resolution.  
In 2003, Brito et al. [70] developed a two-step PCR approach to identify pneumococcal serotypes 
in a fast and cost-effective way, PCR-serotyping, achieving 94.2% agreement with the traditional 
immunological method (Quellung reaction) on their first attempt. Still today the United States Centers 
for Disease Control and Prevention (CDC) recommends both conventional and real-time PCR methods on 
their website for deduction of pneumococcal serotypes and serogroups [71]. Multiple publications 
followed, with incremental improvements such as Real-time PCR and Whole Genome Sequencing (WGS), 
which have been fundamental to support studies surrounding the effects of the 7-valent conjugate 
pneumococcal vaccine (PCV7) released in 2000 and subsequently the 13-valent conjugate pneumococcal 
vaccine (PCV13) released in 2010 [57,72,73]. 
PCR was also used to improve the PBP pattern method used in my studies – PBP Fingerprinting is 
referenced in many publications and executed in various ways, but always based on the PCR amplification 
of the PBP genes, followed by digestion with one or two restriction endonucleases with 4-5 bp recognition 
sites, and typically detected by ethidium bromide staining [74,75] , although earlier versions included 
end-labeling with radioactively labeled 32P [76]. 
RFLP analysis, combined with PCR, was an important early tool in genome mapping, localization of 
genes for genetic disorders, determination of risk for disease, and paternity testing [65] but it has since 
then reached its sunset. Techniques to sequence DNA had been adopted since Sanger’s chain-termination 
technique was published in 1977 [77], but they were very manual, cumbersome and time consuming. 
However, they were advancing rapidly during the late 20th century: the Human Genomic Sequencing 
Project [78], from 1990 to 2003, unleashed methods of rapid and inexpensive DNA Sequencing.  In 
succession, the identification of Single Nucleotide Polymorphisms (SNPs) largely replaced RFLPs in prior 
and novel applications [79–81]. 
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An important molecular method based on sequencing was developed for S. pneumoniae 
epidemiology studies by Enright and Spratt in 1998: Multi-Locus Sequence Typing (MLST) [52]. In this 
method, seven housekeeping genes are sequenced as a sample of genomic variation and are used to 
define the sequence type. MLST proved to be a powerful new approach to the characterization of 
pneumococci, providing molecular typing data that is objective and can be electronically portable 
between laboratories, used to build databases, and establish objective measures of linkage [25,52]. 
Sequencing has greatly evolved into Next-Generation Sequencing (NGS) – a powerful and diverse 
set of technologies which has drastically reduced the cost and difficulty associated with earlier DNA 
sequencing [82–85].  These remarkable advances in nucleotide sequencing technology, have 
revolutionized the field of genomics and created the possibility of Whole Genome Sequencing (WGS) in 
as little as one day. They are widely used in applications such as identification, disease predisposition and 
human lineage in largely commercialized ancestry kits [86]. NGS also has wide applications in disease 
management and healthcare. An example is the technology being developed by Natera, San Carlos, CA, 
USA, combining SNP variability and cell-free DNA detection through NGS to address fundamental 
questions in the fields of Reproductive Health, Oncology and Organ Transplant [87].  
The first pneumococcal genome sequenced was that of a virulent isolate of serotype 4, TIGR4, 
published in 2001 by Tettelin et al.[88]. The ability to sequence multiple whole bacterial genomes through 
WGS brought an important concept to studies of S. pneumoniae and other pathogenic bacteria. The 
notion that pathogenic bacteria relied on a pool of genomes to draw from and adapt to diverse host 
environments was first introduced by Ehrlich et al. in 2005 as the theory of bacterial plurality [89]. This 
theory, later referred to as the distributed-genome hypothesis (DGH) was confirmed for S. pneumoniae 
initially by Hiller et al. in 2007 [90] and Donatti et al. in 2010 [91], and since then by many studies. In May 
2020, the genomes of over 14,000 strains of pneumococcus were publicly available and this number is 
constantly increasing [92]. Data show that S. pneumoniae has a supragenome, or pangenome of typically 
5,000 – 7,000 gene clusters, which is much larger than the genome of any individual strain, with typically 
500 – 1,100 gene clusters; about three quarters of pneumococcal genes are differentially distributed 
across strains. The open pangenome guarantees the species a quick and economical response to diverse 
environments [59,91].  
Whole genome sequence analysis confirmed that genetic exchange occurs both within and across 
the borders of the species. Homologous recombination of short stretches of DNA from related species 
sharing the same ecological niche is the main mechanism of evolution of S. pneumoniae; Streptococcus 
mitis, which also colonizes the human nasopharynx, is the main reservoir of genetic diversity of S. 
pneumoniae outside the species [59,91]. 
I have observed an interesting change in the tone of conclusions from the early-1990s molecular 
typing publications to those in the post-sequencing era. What were mere hypothesis and postulates as 
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to lineages and clone migrations in my publications and those of the time, have now been confirmed and 
are presented with certainty - with in-depth analyses of phylogenies and distinction from horizontal 
recombination versus vertically acquisition of substitutions. The technological inaccessibility to data led 
us to publish conclusions with unproven hypotheses in the early 1990s, but WGS has repaired this 
vacuum. This is very evident in a 2011 publication in the journal Science about pneumococcal evolution, 
by Croucher et al. [58]. 
Since the beginning of this century, Real-time PCR has developed greatly and established itself as 
the method of choice for identification and characterization of organisms. It has a very quick turnaround 
time, and the ability to multiplex and detect multiple genes or organisms in a single reaction. When 
coupled with melting curve analysis and with the right probe design, it can provide discrimination to the 
level of point mutations. In addition, with the appropriate controls, it can be used to quantitate the 
starting nucleic acid material, increasing its applications to DNA quantitation. When combined with 
reverse-transcription (Real-time RT-PCR) it can be used in RNA applications and gene expression. An 
illustration of real time PCR curves is shown in Figure 1.14. 
 
Figure 1.14. Example of a Multiplex Real-Time PCR Graph 
Each color represents a probe labeled with a different fluorescence dye to detect a specific target 
gene. The X-axis represents the PCR cycle and the Y-axis represents the florescence increase. The 
graph lines portray the logarithmic PCR amplification of the target in real time, as detected by the 
accumulation of fluorescent probe. Lines of the same color that are separated by approximately 3-4 
cycles represent amplifications of tenfold serial dilutions of DNA template. Adapted from Solis 
Biodyne 5x-HOT-FIREPol®-Multiplex-qPCR-Mix [93]. 
 
Real-time PCR is the gold-standard culture-independent assay for S. pneumoniae identification, 
targeting the major autolysin lytA, the pneumococcal surface adhesion psaA, and the permease piaB 
genes, among others [94–96]. In 2019, Tavares et al. developed a new real-time PCR assay targeting the 
putative transcriptional regulator gene SP2020 increasing the specificity of the identification by 0.2% to 
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99.8% with the single new gene, and reducing the misidentifications to none (0/823) when combined 
with lytA [94].  
Real-time PCR is also widely used in molecular diagnostic tools outside of S. pneumoniae. For 
example, it is used to identify infection and antibiotic resistance in the assay commercialized by Cepheid 
Inc., Sunnyvale, CA, USA, for the detection of Mycobacterium tuberculosis [97–99]; this assay is reviewed 
in Chapter 3.  
While each of the techniques outlined here has brought amazing advances in the molecular biology 
field, and although it is undeniable that WGS has changed science and the world, I think that the true 
revolution of the 21st century was brought on by something that is common between many of those 
techniques: the combination of scientific specialties. The powerful techniques we see today, with their 
efficiency, high-throughput and accuracy combine multiple platforms of expertise. They rely on amazing 
combinations of Engineering with Physics, Chemistry, and Biology, and produce complex results that are 
processed through Computational/Mathematical Algorithms and Statistics. In my early twenties, when I 
was in university studying for my Chemistry-Biotechnology degree, much was talked about the old rivalry 
between Physicists and Chemists. In times that we could refer to, one was either one or the other. I did 
not notice it then, but my degree in Biotechnology already relied heavily in the combination of fields: 
biotechnology, biochemistry, and enzymology are some examples. Today, there are full degrees in cross-
functional subjects, such as Bioengineering and Biostatistics.  Those cross combinations of fields are 
everywhere in science today and have become complex; the truly powerful results tend to come from 
cross-functional collaborations, diverse combinations of brilliant minds that are not only experts in their 
field but have the emotional mindset and generosity to be able to truly collaborate and trust others, 
forming scientific bridges and creating access to cutting-edge technologies and large databases of 
information. This collaborative approach has brought a paradigm shift to the way we do science in the 
21st century, and it is only hindered by the often-limited access to patented technology and for-profit 
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1. Introduction  
1.1. Tuberculosis 
Tuberculosis (TB) is an infectious disease, and one of the oldest recorded human diseases. 
According to the World Health Organization, TB has recently been one of the top ten causes of death 
worldwide, and the leading cause of death from a single infectious agent [100]. In 2019, 1.4 million people 
died from TB [101]. 
TB is acquired by inhalation of infectious aerosol particles. It is estimated that about a quarter of 
the world’s population is infected with the disease [100]. Most individuals mount an effective response 
in the lungs leading to a dormant form of the disease - latent tuberculosis; these individuals show no 
symptoms and do not transmit the disease to others. However, about 5 to 10 percent of the infected 
individuals eventually progress from latency to an active state. Immunocompromised individuals have a 
higher risk of developing active TB, and the prevalence of the active form of the disease is strongly 
associated with poor social and health conditions [100,102,103]. 
The predominant form of TB affects the lungs and is referred to as pulmonary TB. However, in 5-
20% of the cases,  infection may develop in other body sites and lead to Pott’s disease (spinal and bone 
deformities), scrofula (swelling of the lymph nodes in the neck), meningitis (central nervous system), or 
other less prevalent forms of extrapulmonary TB [104]. 
The German microbiologist Robert Koch isolated the tubercle bacillus in the late 1800s and 
reproduced the disease by inoculating it into laboratory animals, announcing to the Society of Physiology 
in Berlin on the 24th of March of 1882 that the bacillus Mycobacterium tuberculosis (Mtb) is the cause of 
tuberculosis. This discovery triggered many developments in the following decades such as the Pirquet 
and Mantoux tuberculin skin tests, the Bacillus Calmette-Guérin (BCG) vaccine, and anti-tuberculosis 
drugs such as streptomycin. Koch was awarded the Nobel prize in Medicine in 1905 [105,106]. 
1.2. History of the tuberculosis disease 
TB is an ancient disease. Egyptian mummies that are 4,400 years-old show skeletal deformities 
typical of tuberculosis, and abnormalities like Pott’s lesions are clearly illustrated in early Egyptian art 
[105].  Written descriptions of humans with TB-like symptoms date as far back as 3,300 years ago in 
writings from India, persisting through recorded ancient history in 700 B.C. clay tablets from the Assyrian 
Empire, in Hippocrates’s detailed accounts of phthisis (an ancient name for tuberculosis) in 500 B.C. 
Greece, and in 2300 year-old writings from China [104,105]. 
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Recent genomic findings indicate that TB is even older than we thought. Several publications since 
2005 have challenged a prior belief that TB originated in animals and was transferred to humans 10,000 
years ago, during the Neolithic transition. A study by Gutierrez et al., using DNA sequence data of six 
housekeeping genes, proposed that an ancient strain, an ancestor of Mtb, would have originated about 
3 million years ago in East Africa [107]. Their conclusions have been contested [108] but multiple other 
evidence summarized in 2012 by Gagneux [109] points to a pre-historic African origin, as well as a host-
pathogen coevolution. It is worth mentioning that publications from 2008-2009 discuss a 500,000-year-
old fossil of Homo erectus discovered in Turkey with bone lesions that may be attributed to TB, albeit 
among other causes, raising questions around the possibility of TB infections predating modern humans 
[110,111]. 
Throughout history, TB remained sporadic up to the 18th century; then it started to increase due to 
higher population density, unfavorable living conditions and the industrial revolution. By the 19th century, 
then known as consumption, tuberculosis became epidemic, accounting for nearly 25% of all deaths in 
London for about two decades in the early 1800s [112,113]. Consumption affected especially infants and 
young adults, which exhibited the familiar symptoms of chronic cough, fever, weight loss and extreme 
paleness; tuberculosis is widely mentioned, sometimes romanticized, in the art and literature of the time 
(example in Figure 2.1), giving rise to tragic heroines such as Mimi in Puccini’s La Bohème who dies of 
consumption in the opera’s last scenes.  
 
Figure 2.1. Image of the painting The Sick Child 
By Edvard Munch, 1885–86 [114]. 
 
During the 20th century, the incidence of TB started to decrease rapidly in developed countries 
thanks to improved nutrition, housing conditions and overall health. The introduction of the BCG  vaccine 
in 1921 and the use of antibiotics, such as streptomycin in 1943, isoniazid in 1952, and rifampicin in 1963, 
greatly contributed to the decrease [103]. However, in the 1980s, the incidence in TB increased again to 
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concerning levels due to the HIV pandemic, the deterioration of health conditions in large cities and the 
appearance of resistance to antibiotics [103]. 
1.3. Tuberculosis in the world today 
TB is a major public health problem worldwide, with a natural reservoir in 25-30% of the world’s 
population with latent forms of the disease, and increasingly sparse treatment options due to the global 
pervasiveness of multi-drug resistant strains. At a crowded news conference in London on April 23rd, 
1993, the WHO declared a global emergency for the first time in history, unleashing a series of media 
coverage and increasing public awareness for TB and drug resistance [115]. 
An estimated 10 million people fell ill with TB in 2018, and about 1.2 million died, as reported by 
the WHO in 2019. Most TB cases occur in developing countries, where conditions are poor, and treatment 
is difficult. Graphic illustrations of TB prevalence during the year of 2018 are shown in Figure 2.2. 
Prevalence is highly associated HIV and AIDS - among all TB cases in 2018, 8.6% were people living with 
HIV [100]. 
  
Figure 2.2. Graphs showing the prevalence of TB cases in 2018 
Graphs generated with data obtained from the WHO Global TB 2019 Report [100]. 
Leaders of all member states of the United Nations (UN) have committed to ending the global TB 
epidemic by 2030. Progress is being made and some countries are on track to reach this goal; however, 
the worldwide pace towards milestones is slow. Additional resources are needed, and the topic, as of the 
release of the Global Tuberculosis WHO Report in 2019, was highlighted for discussion at the UN General 
Assembly in 2020 [100]. The Global Tuberculosis WHO Report of October 2020 again confirms that several 
milestones have been met, and the annual TB incidence rate and number of deaths are falling globally 
(9% and 14% respectively in 2019), but they are not declining fast enough to reach the 2015 to 2020 
reduction milestones of 20% for incidence rate and 35% for number of deaths [116].  
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In 2020, TB continues to pose a huge public health risk, potentially made worse with increasing  
concerns in the context of the increased burden of Covid-19 on hospitals and access to medical care, and 
potential coinfection with SARS-CoV-2 [116–118]. 
1.4. The bacillus Mycobacterium tuberculosis 
Mtb is an obligate aerobic and facultative intracellular bacillus (Figure 2.3). With humans as a single 
reservoir, Mtb is usually found in large numbers in pulmonary cavities and carried by alveolar 
macrophages to the host’s lymph nodes [119,120]. 
 
Figure 2.3. Electron micrograph of Mycobacterium tuberculosis 
Magnification 15549X. Image adapted from Todar, 2015 [14]. 
 
Mtb and other mycobacteria have a cell wall which includes peptidoglycan, such as typical Gram-
positive bacteria, but it also contains a high content of complex lipids, including mycolic acids, cord factor 
and wax-D, which are significant determinants of Mtb virulence. These lipids do not stain well with Gram-
stain, and therefore mycobacteria have traditionally been identified through Zielh-Neelsen’s staining 
method and classified as acid-fast, instead of Gram. The high concentration of lipids in the cell wall 
of Mtb have also been associated with impermeability, resistance to certain chemical treatments and 
survival inside of macrophages [14].  
Mtb cultures are slow growing, with generation times of approximately 20 hours in laboratory 
media and taking 3 to 8 weeks to show visible colonies on agar plates [119,120]. As shown in Figure 2.4, 
Mtb colonies have a waxy appearance due to the high levels of mycolic acids [14]. 
 
Figure 2.4. Colony morphology of Mycobacterium tuberculosis 
Showing the characteristically rough and waxy colony appearance. Image adapted from Kubica, 1976 [121]. 
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The genome of Mtb has been known for its high GC content. In 1998, S. T. Cole et al. [122] published 
the complete genome sequence of the H37Rv, the strain of choice for laboratory Mtb studies, confirming 
the GC content as 65.6% and reporting that the genome is comprised of 4,411,529 base pairs and 
encoding approximately 4,000 genes, many devoted to the production of enzymes involved in lipid 
metabolism [122]. 
1.5. The Mycobacterium tuberculosis complex 
It is now known that tuberculosis affects several mammalian hosts and is caused by a group of 
phylogenetically closely related bacteria – the Mycobacterium tuberculosis complex (MTBC) [109,122].  
In humans, TB is caused primarily by M. tuberculosis and M. africanum, with the latter having a 
higher prevalence in West Africa. Other members of the MTBC include M. bovis (cattle), M. caprae (sheep 
and goats), M. microti (voles) and M. pinnipedii (seals and sea lions), expanding to include additional 
species frequently and to varying degrees in the literature. These infectious agents do not transfer disease 
easily from host-to-host outside of their preferred host species, suggesting a strong adaptation of the 
pathogen to the host; however, it should be noted that Mtb has been isolated from various animal species 
and M. bovis can cause disease in humans, albeit with no host-to-host transmission documented [109]. 
MTBC member species display different phenotypic characteristics and affect various mammalian 
hosts, but they represent one of the most extreme examples of genetic homogeneity, with rare 
nucleotide variation and no significant trace of genetic exchange among them [107,109,122]. This low 
level of genetic variation suggests that the entire population may have developed from a common 
ancestor [107,109]. 
M. bovis isolated from a sick cow was used by Albert Calmette and Camille Guerin to generate a 
non-virulent variant, through 230 laboratory passages, yielding the Bacillus Calmette-Guerin (BCG). BCG 
was used for the first time in humans in 1921 as a TB vaccine and the studies were published in 1931 
[123]. Molecular studies confirmed later that significant portions of the M. bovis genome are missing in 
BCG [124]. 
Because of the risk of infection, the culture of Mtb is classified as a Biosafety-level-3 (BSL-3), 
requiring special air filtration and extensive gowning and ungowning procedures for laboratory access. In 
addition, Mtb is a slow growing bacterium, taking 3-8 weeks to yield a visible colony. Therefore, molecular 
studies of the MTBC have largely used a non-virulent and fast-growing laboratory model as a surrogate: 
Mycobacterium smegmatis. This species shares more than 2000 homologous genes with Mtb, has the 
same cell wall structure as species in the MTBC, and is easily manipulated with plasmids and mobile 
genetic elements by transformation [125]. 
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2. Tools to Study Mtb Virulence 
2.1. Background 
Much of the work carried-on in the PHRI laboratory where I worked from 1994 to 1997 under the 
direction, mentorship, and extraordinary inspiration of Dr. Eugenie Dubnau, had the ultimate goal of 
searching for Mtb genes involved in virulence. It typically involved cloning mycobacterial genes from Mtb 
or from M. bovis BCG into mycobacterial plasmid vectors and observing their effect when overexpressed 
in mycobacterial hosts. The team had expertise in the molecular biology tools that were then relevant, in 
the culture of mycobacteria, and access to a Biosafety-level 3 laboratory where infectious cultures of Mtb 
could safely be propagated. My work centered around genetic manipulations, cloning, and generation of 
genomic libraries, and was enhanced by collaborations with expertise in complementary subjects.  
For example, in the work reported in 1997 in the journal Molecular Microbiology [126], I was 
involved in the isolation and sequence of a cluster of four genes from BCG coding for methyl transferases, 
and subcloned it in M. smegmatis. Collaborators complemented the work by confirming biochemically 
that the gene cluster was involved in the synthesis of mycolic acids, proposing a model for the pathway 
of biosynthesis of mycolic acids in BCG. 
In another example, I generated a genomic library of Mtb that was used for selection in 
macrophages [127] and mouse lungs [128] by collaborators, where the identification of promoters 
specifically upregulated during infection provided clues to genes potentially involved in virulence. The 
construction of the library in the promoter trap and work in macrophages is described in detail in the 
sections below. 
2.2. Construction of an Mtb library in a promoter trap 
I used an in vivo expression technology (IVET) system [129–131] in my hunt for Mtb genes involved 
in virulence, that could later be used as targets for diagnosis and treatment of TB. I created a promoter 
trap to select for Mtb genes specifically upregulated during growth in human macrophages; selection was 
based upon increased expression of inhA, driven by promoters specifically upregulated during infection.  
The gene inhA from M. smegmatis had been previously cloned and studied [132]. It codes for an 
enoyl-ACP reductase, which is required for mycolic acid biosynthesis and is a major target for the 
antibiotic isoniazid in Mtb. Overproduction of this enzyme confers resistance to isoniazid in M. smegmatis 
[132] and, as we suspected and were able to confirm during this study, in Mtb as well. 
For the construction of the promoter trap, I started by inserting a promoterless PCR-amplified M. 
smegmatis inhA gene [132] into pYUB378, an Escherichia coli - Mycobacterium shuttle vector conferring 
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kanamycin resistance in both organisms [133]. The resulting plasmid, pJD32, had a unique BamHI 
restriction site upstream of the promoterless inhA gene which was used for further constructs. The 
approximate structure of the pJD32 construct is illustrated in Figure 2.5. This plasmid was also used in 
our studies as a negative control. 
To create a positive control, I cloned the hsp60 promoter (Phsp60) from M. bovis BCG into the 
BamHI site (Figure 2.5). This promoter, driving the production of a highly conserved essential protein in 
BCG, is expressed constitutively at high levels when present on a multicopy plasmid [134]. The resulting 
construct, pJD33 is therefore expected to confer isoniazid resistance to its Mycobacterium hosts in any 
condition. 
 
Figure 2.5. Schematic depiction of the promoter trap constructs  
Promoter trap constructs were used in the strategy to identify Mtb genes upregulated in human 
macrophages. BamHI is the unique restriction site selected for cloning. InhA is a gene from M. 
smegmatis.  Phsp60 is the hsp60 constitutive promoter from BCG. Location of the other genetic 
elements, oriE (origin of plasmid replication in E. coli), oriM (origin of plasmid replication in 
mycobacteria) and Km (Kanamycin resistance), is shown for illustrative purposes only and may not 
be accurate. Description of the cloning activities and relevant genetic element functions are 
provided in the main text. 
 
I built a library of Mtb genomic DNA in the pJD32 promoter trap, to later screen and select for 
virulent genes. I started by culturing the H37Rv strain of Mtb in 7H9 broth (supplemented with albumin, 
dextrose, NaCl, and Tween 80) and incubating on a rotator at 37⁰C [135]. H37Rv is a virulent strain, so all 
H37Rv propagations were carried in the BSL-3 laboratory. I purified genomic DNA from H37Rv and 
subjected it to a partial digestion with the SauIIIA restriction endonuclease, obtaining an assortment of 
small DNA fragments. These were then cloned into the BamHI site of pJD32 (Figure 2.5) in Escherichia coli 
(E. coli). The resulting plasmid library of 106 clones in E. coli was estimated by PCR analysis as containing 
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an average insert size of 300 bp (between 100 and 500 bp), at a minimum insertion rate of 62%. The 
library was therefore estimated to contain 186 Mb of Mtb genomic DNA. For an organism with a genome 
of 4.4 Mb, this library in E. coli contained a genomic over-representation greater than 42-fold. 
The plasmid library, as well as the positive and negative controls, were then used to independently 
transform Mtb H37Rv via electroporation [135]. Initial selection for the plasmid was done using 
kanamycin at 10 μg/mL in broth culture.  To verify the quality of the library in Mtb, an aliquot of the 
transformation mixture was plated, and a total of about 9 x 104 Mtb clones were obtained. Since the 
insertion frequency was 62% with an average insertion size of 300 bp, this library was calculated to 
represent the entire genome of Mtb almost four times (16.7 Mb of the 4.4-Mb genome).  
Since the goal was to use the plasmid library to identify Mtb promoters, the H37Rv library was 
verified for the frequency of promoter inserts by plating with selection for isoniazid at 1 μg/mL (a high 
concentration, to identify strong promoters). It was expected to be low (due to the need for correct 
orientation upstream of inhA) and determined to be 0.01% - this is presumably the rate of clones 
containing a strong promoter upstream of inhA which was active when Mtb was grown on plates. 
2.3. Verification of performance of controls 
Strain H37Rv of Mtb, carrying pJD32 (promoterless inhA, negative control) or pJD33 (inhA driven 
by Phsp60, positive control) was cultured with and without isoniazid, in broth culture and in THP-1 human 
macrophage cells by my colleagues.  
As expected, the culture carrying the negative control (pJD32) remained sensitive to isoniazid, and 
this culture did not grow in broth or macrophages in the presence of the antibiotic.  
The positive control (pJD33) conferred resistance to isoniazid to Mtb as previously reported for M. 
smegmatis [132]. This phenotype was confirmed in both broth and macrophages, and results are shown 
in Figure 2.6. These results show that as previously reported for M. smegmatis [132], overproduction of 
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Figure 2.6. Growth of Mtb H37RV carrying the promoter trap constructs 
Growth of H37RV carrying the negative control plasmid pJD32 and the positive control plasmid pJD33 in 
broth (A) and in THP-1 human macrophages (B) as determined by optical density of the culture. As expected, 
the promoterless inhA negative control (pJD32) is sensitive to isoniazid in both growth conditions, and the 
inhA gene preceded by the constitutive promoter (pJD33) confers resistance to isoniazid in both growth 
conditions. It should be noted that Mtb carrying the plasmid with no promoter driving inhA (pJD32) is more 
sensitive to isoniazid in broth culture (A) than in THP-1 macrophage cells (B). Figure replicated from Dubnau 
et al., 2002 [127]. 
 
In conclusion, the promoter trap conferred isoniazid resistance through overexpression of inhA 
only in the presence of a promoter; it was therefore expected to be suitable for the identification of Mtb 
promoters induced during infection, as intended in later experiments. 
2.4. Selection of isoniazid resistant Mtb clones during infection of macrophages 
A culture from the library was used to infect THP-1 cells that had been differentiated into 
macrophage-like cells by collaborators.  
Clones that survived a 5-day treatment with isoniazid at 0.5 μg/mL were isolated, diluted into 
broth, used to reinfect THP-1 cells, and subjected to isoniazid treatment again. Passaging of the library in 
this manner was repeated for a total of four rounds. In between each round, clones were screened 
individually for complete sensitivity to isoniazid on agar plates. 
Clones that survived isoniazid treatment in macrophages and were isoniazid sensitive on plates, 
and that were confirmed to contain DNA inserts upstream of inhA, as determined by direct PCR analysis, 
were selected.  
The inserts in these plasmids were sequenced and compared to the Mtb H37Rv genome database. 
After the four rounds of selection for expression in macrophages, approximately two thirds of the 65 
clones contained sequences 5’ to an open reading frame in the correct orientation for transcription of 
inhA, suggesting the presence of promotors driving the expression of inhA during infection of 
macrophages. A list of the 43 open reading frames found downstream from these putative promoter 
sequences is shown in Table 2.1.  
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Table 2.1. Genes identified by isoniazid selection in macrophages 




Differential expression between agar culture and macrophages was verified for wild-type Mtb 
H37Rv through RT-PCR, for 13 of the 43 putative promotors identified by the selection method. Eight of 
the 13 loci/genes tested were confirmed to be upregulated more than two-fold during growth in 
macrophage cells relative to growth in broth culture (Rv2224c, Rv3237c, Rv3321c, Rv2520c, pckA, 
echA19, fadA4, and aceA), but the other 5 appeared to be equally expressed or down-regulated in 
macrophages. These results confirm that the promoter trap system for macrophage selection was an 
efficient strategy in the identification of candidate Mtb genes involved specifically in macrophage 
survival, and potentially virulence, but also that further validation methods are necessary to confirm the 
differential expression. 
This work was published in 2002 in Infection and Immunity, under the title “Mycobacterium 
tuberculosis Genes Induced during Infection of Human Macrophages”[127]. 
Chapter 2. Molecular Biology Tools for studies in Mycobacterium tuberculosis Virulence 
 42 
3. Conclusions 
My contribution to this work was to help engineer and construct a molecular biology tool, the 
promoter trap, and then build an Mtb genomic library, to enable the selection of potentially virulent 
genes in macrophage studies performed by my colleagues. The invention of the promoter trap is credited 
to my phenomenal mentor at the PHRI, Dr. Eugenie Dubnau, who was the principal investigator and 
fundamentally responsible for the architecture of this strategy. 
The promoter trap technology that we used - in a multicopy plasmid - can result in artifacts because 
it does not necessarily reflect normal gene expression from the chromosome. Other restrictions may also 
have limited our results, such as the selection of clones that were resistant to isoniazid in macrophages 
but completely sensitive in vitro (in other words, we selected for on/off promoters and not exactly for 
increased expression). However, using this tool, my colleagues and I were able to identify eight loci/genes, 
many of which were found to be conserved in infectious species of Mycobacterium, beneficial and 
sometimes essential for infection, or involved in pathways deemed critical for survival in the host (see 
section 4.1. Further findings).  
When witnessed through the lens of the technology resources that are available to researchers 
today (see section 4.2. Gene expression profiling), the strategy that we developed in the mid-nineties was 
extremely manual and slow, but I am incredibly grateful for having been a part of it. The use of promotor 
traps and IVET systems was new at the time. These techniques were early models of bioengineering, 
examples of applied biotechnology at its best, and the predecessors of amazing architectures in molecular 
biology that are used today in broader applications, such as adenoviral vector systems engineered to 
deliver vaccines and genetic therapies that save human lives [136], or CRISPR-Cas systems, tailored from 
prokaryotic adaptive immune systems into an incredibly powerful toolbox for eukaryotic applications, 
from genome editing, to RNA targeted diagnostics [137]. 
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4. Further Considerations 
4.1. Further findings 
The Mtb genomic library that I built went on to support additional research findings. In a posterior 
study using this promoter trap library, an additional 56 genes were identified from Mtb that are 
preferentially expressed in live mouse lungs. Some of them were confirmed to be differentially expressed 
through quantitative real-time PCR [128]. 
One of the 8 genes identified to be up-regulated in macrophages, fadA4, which codes for Acetyl-
CoA acetyltransferase, was also in the group of genes identified in the mouse lung study [128], 
strengthening the notion that it may be involved in host infection and virulence. 
Rv2224c was found to be conserved between Mycobacterium species M. leprae, M. bovis and M. 
avium paratuberculosis, and  to encode a probable secreted protease associated with the cell envelope 
by comparative studies [138]. It was confirmed to be critical for Mtb virulence: disruption 
of Rv2224c compromised the intracellular survival of Mtb in macrophages, increased its susceptibility to 
lysozyme, and also led to prolonged survival and highly reduced lung pathology of infected mice 
[139,140]. 
 Rv3237c encodes a conserved protein with some similarity to putative potassium channel proteins 
from other species. It was found to be a non-essential gene for in vitro growth by analysis of saturated 
Himar1 transposon mutagenesis [139], but no other information was found in the literature. 
The locus Rv3321c is now known as gene vapB44 [141] encoding antitoxin VapB44. Although not 
proven to be essential for infection, this protein has been associated with a group of toxin-antitoxin (TA) 
modules, which are bi-cistronic operons that may act in stress physiology by serving as metabolic 
regulators of growth. Mtb possesses an unusually large and diverse complement of TA modules 
[142,143]. 
Rv2520c is conserved in mycobacterial strains and predicted to encode an integral membrane 
protein [139]. 
pckA codes for phosphoenolpyruvate carboxykinase (PEPCK). Deletion of the pckA gene of M. bovis 
BCG led to a reduction in the capacity of the bacteria to infect and survive in macrophages, and mice 
infected with BCG carrying the deletion were able to reduce the bacterial load much more effectively 
than mice infected with the parental wild-type bacteria [144]. This attenuated virulence of the BCG 
deletion mutant is in line with the promoter trap Mtb library results, supporting the hypothesis that pckA 
is involved in Mtb virulence. 
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echA19 codes for a putative enoyl-CoA hydratase, whose absence partially inhibits the process of 
degradation of cholesterol and β-sitosterol. Studies show that cholesterol may play an important role in 
the host-pathogen interaction and Mtb pathogenesis [145]. 
The probable isocitrate lyase encoded by aceA may play a part in the Glyoxylate cycle. Other 
isocitrate lyases have been described with roles in this cycle, and found to be essential for host 
persistence and virulence of Mtb [139,146,147]. 
In summary, all eight genes show some indication of importance for Mtb, from simply encoding 
conserved proteins to having been confirmed to be essential for virulence. 
4.2. Gene expression profiling 
The promoter trap with isoniazid resistance is a tool for gene expression profiling from a time when 
large data analysis was not readily available to researchers - selection through antibiotic resistance 
provided the means for downsizing the number of results to only relevant hits, but it carries potential 
collateral artifacts stemming from overexpression on a multicopy plasmid. 
Today, gene expression profiling tools are used to screen differential expression in large-scale. RNA 
sequencing (RNA-seq) has facilitated genome-wide expression profiling, including the identification of 
novel and rare transcripts like noncoding RNAs and novel alternative splicing isoforms [148]. Other 
methods rely on cDNA arrays and real-time quantitative RT-PCR. 
These methods are based on previously described technologies (section 6.2. Evolution of typing 
techniques), but their novelty is that through the aid of computational analysis and biostatistics, 
differential expression can be determined without the use of in vivo artifacts and in large scale – the 
whole transcriptome can be analyzed in a single setting. The techniques unequivocally underline the 
perspective I highlighted in the last paragraph of section 6.2 in Chapter 1 – they are built on the bridging 
of technologies and combination of knowledge across many fields, including Engineering, Computational 
Sciences, Statistics, Biology, Chemistry and Physics. 
4.3. The Public Health Research Institute 
The PHRI is now part of the New Jersey Medical school and Rutgers University, and continues to 
pursue its research mission to help eliminate infectious diseases from spreading across the planet [149].  
Standing out from many exceptional discoveries at the PHRI, are the invention of molecular beacon 
probes, now widely used in multiplex real-time PCR, which were developed while I worked there by 
cherished colleagues on the same floor [150]. The PHRI and Rutgers University faculty also invented and 
co-developed the Cepheid Mtb detection assay for commercialization. Both are included in the next 
chapter of this report. 
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The four years I worked at the PHRI were fundamental in my development, my scientific approach 
to problem solving, and ultimately greatly impacted the direction of my career and who I am at my core 
today. The environment was extraordinary for any young scientist – the floor was brewing with amazing 
mentors, who provided an umbrella of scientific knowledge, a high standard of ethical principles, 
friendship, camaraderie, and were models of collaboration for the greater good of science. My work was 
incredibly interesting and motivating, and it taught me a lot: about biology at a very fundamental level, 
how to methodically control experiments, how to stay focused on a long-term goal through a day-to-day 
labyrinth of details and plans, and how to maintain my scientific and ethical principles in the forefront of 
everything I do. This gem in Manhattan, the PHRI, then housed in the New York City Health Department 
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From 2004 to 2019 I worked in the Product Transfer Department at Cepheid, Sunnyvale, California, 
USA.  
The products that Cepheid develops and produces are individual cartridges that integrate cell lysis, 
nucleic acid purification, Real-Time PCR, fluidics, software, and data analysis algorithms in order to detect 
(and sometimes quantify) the presence of specific nucleic acids in human samples. The products are 
aimed at aiding medical practitioners in the diagnosis of diseases or conditions.  
My work involved the transfer of products from Research and Development (R&D) to production 
and post-launch improvements: establishing the production line processes, designing and validating the 
quality control methods and specifications, performing hands-on failure investigations, as well as leading 
cross-functional teams with various skills from molecular biology to software integration and automation 
line engineering.  
The XpertMTB assay line includes a few molecular diagnostic kits options which, in a single step, 
can detect Mycobacterium tuberculosis and characterize antibiotic resistance patterns in patient sputum 
samples, aiding doctors in the appropriate and effective selection of treatments.  
Cepheid’s assays are part of a connected system where the reagents are contained in a cartridge 
that performs sample preparation as well as real-time PCR detection. This cartridge works when placed 
in the GeneXpert – a family of instrument systems that is designed to provide real-time PCR at varying 
scales, from point-of-care detection in doctor’s offices to large volume laboratories. 
The work that I performed to commercialize and consistently produce the many sub-types of the 
XpertMTB and other Cepheid assays has many elements that I will not disclose, respecting Cepheid’s 
confidentiality. However, the real-time PCR functionality of the XpertMTB assays was published by their 




2.1. Antibiotic resistance and Mtb 
The Mtb bacillus has developed multiple mechanisms enabling antibiotic resistance since the use 
of antibiotics became widespread in the mid-20th century, unfortunately a prevalent reality common to 
most infectious bacterial agents including, as previously mentioned, S. pneumoniae. 
During the 1990s, multidrug-resistant tuberculosis (MDR-TB) emerged worldwide as a threat to TB 
control; MDR-TB is defined as a form of TB that is resistant to at least the two front line antibiotic TB 
treatments: isoniazid and rifampicin [151,152]. 
In the 2000s, extensively drug-resistant tuberculosis (XDR-TB) emerged. XDR-TB is a form of TB 
which is resistant to at least four of the core anti-TB drugs: isoniazid, rifampicin, any of the 
fluoroquinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-
line drugs (amikacin, capreomycin or kanamycin) [152]. By 2016, XDR-TB had been reported in 123 
member states of the World Health Organization, with data suggesting that about 6.2% of MDR-TB cases 
worldwide are XDR-TB. XDR-TB patients can be cured, but with the current drugs available, the likelihood 
of success is much smaller than in patients with ordinary TB or even MDR-TB. Cure depends on the extent 
of the drug resistance, the severity of the disease and whether the patient’s immune system is 
compromised [152]. 
Methods to rapidly identify Mtb and characterize the antibiotic resistance pattern in each patient 
are important from an individual health perspective, and critical from a public health standpoint.  
2.2. Rifampin resistance and MDR-TB 
Rifampicin monoresistance is extremely rare, and usually preceded by development of resistance 
to isoniazid, so rifampicin resistance is used as the marker for identification of MDR-TB [97,153–156]. 
It has been shown that 95 to 98% of rifampicin resistant strains have mutations, insertions or 
deletions in an 81-bp core region of the rpoB gene, named the rifampicin resistance determining region 
(RRDR), encoding a specific 27 amino-acid sequence of the β-subunit of the RNA polymerase [153,156]. 
These are often point mutations in specific codons [156]. In contrast, drug susceptible strains always 
display the wild-type sequence in this region [157].  
For these reasons, the rpoB gene, and specifically the RRDR, is an ideal target for molecular 
screening of MDR-TB. 
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2.3. Real-time PCR assays 
Real-time PCR is a powerful technology, at present widely used for many applications including the 
identification of organisms, as detailed in Chapter 1, section 6.2. Evolution of typing techniques. 
Real-time PCR gets its name for the ability to monitor the PCR amplification of a targeted DNA 
template during the reaction, i.e., in real time.  
Early methods of real-time PCR included the use of intercalation dyes such as SYBR Green, which 
became fluorescent upon the non-specific incorporation into any double-stranded DNA molecule. By 
monitoring the increase in fluorescence throughout the PCR reaction, one can follow the increase in the 
amount of double-stranded PCR product. This method has some problems in that it relies solely on the 
specificity of the primers to identify the correct target. 
Improved methods more frequently used currently rely on the use of sequence-specific DNA 
probes, which add to the specificity of the PCR primers by matching the target. These short nucleotide 
probes typically contain a mechanism that will greatly increase the amount of fluorescence emitted only 
if DNA amplification of the specific target occurs.  
There are numerous types of probes, many including a fluorophore chemical component in one 
end of the probe and a fluorescence quencher on the other end. In a molecular beacon [150], the probe 
is designed to include complementary nucleotides on each end and form a hairpin that brings the 
quencher close to the fluorophore, greatly reducing the emission of fluorescence; in the presence of 
target amplified from the primers, the probe is designed to selectively hybridize to the target, breaking 
the harpin and therefore separating the quencher from the fluorophore, inducing a dramatic increase in 
the amount of fluorescence emitted (Figure 3.1).  
 
 
Figure 3.1. Illustration of the mechanism of Molecular Beacon probes  




The use of different fluorophores (with separate fluorescence emission wavelengths) attached to 
different specific probes, lets several different PCR reactions be monitored in the same reaction tube. 
This powerful technique called multiplexing, allows for the simultaneous detection of different target 
sequences in a sample, and for the design and inclusion of internal controls in an amplification. 
The device needed for a real-time PCR reaction is a PCR thermal cycler equipped with a detection 
system that can read fluorescence throughout the reaction. The typical unit of measure of real time PCR 
is Ct, which stands for Cycle threshold, and represents the PCR cycle number at which the fluorescence 
crossed a nominal threshold level. This threshold level varies; it is assigned to represent the level of 
fluorescence that is minimally sufficient to distinguish a negative reaction (one where the probe does not 
detect the target) from a positive reaction (where the probe detects the target). 
In a well-designed conventional or real-time PCR system, with balanced melting temperatures of 
primers and probes, optimum buffer conditions for the DNA polymerase, and optimal temperatures and 
cycle durations, mathematical perfection can be approached, and amplification of the target is precise. 
The higher the concentration of target in the reaction at the starting point, the earlier the threshold will 
be reached. Real-time PCR has the ability to quantitate the initial amount of target material added to the 
reaction because it inversely correlates to the Ct. Mathematically, a 10-fold increase in the amount of 
template results in a 3.3 decrease in the Ct (within a serial dilution range for the template). Dose response 
curves and internal controls are some of the methods used to facilitate quantitative real-time PCR.  
The high accuracy, high sensitivity, high specificity, low turn-around-time, and low cost of a real-
time PCR reaction make it a perfect candidate for use in multiple applications. Furthermore, real-time 
PCR systems may be designed to discern point mutations. For these reasons, real-time PCR is widely used 
in the molecular diagnostics field, and I will describe below an elegant system in use worldwide for the 
detection of Mtb present in patient sputum samples. 
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3. MTB/RIF Assay 
3.1. Mechanism of detection of Mtb and rifampin resistance  
Several publications described assays designed to allelic discriminate mutations in the rpoB gene 
sequence, and were validated in population studies as highly predictable of MDR-TB [154,155,157]. Later 
on, Piatek et al. developed a rapid closed-tube real-time PCR assay using molecular beacons to detect 
rpoB mutations [158,159]. Molecular beacons are able to detect amplicons as they are synthesized during 
real-time PCR and can discriminate between DNA sequences that differ from one another by as little as a 
single nucleotide substitution [158,160]. Five allele discriminating molecular beacons were designed 
against the RRDR of the rpoB gene [159]. 
Each of the five molecular beacon probes contained a 15-20 nucleotide sequence designed to 
collectively span the entire wild-type rpoB RRDR 81-bp region, with overlapping sequences of 1-3 bases. 
The probes detected the wild-type version of the gene and not a mutant with a single base change [159]. 
To increase the specificity (minimize cross-amplification of non-tuberculosis Mycobacterium 
species) and to maximize mutation detection, the sequences of the primers and probes were modified 
by Helb et al. [97] to incorporate a heminested PCR - two successive reactions where the product of the 
first PCR reaction is used as template for the second reaction, and a third primer is designed to match a 
binding site nested within the first amplicon [97]. 
Bacillus globigii spores, as well as an assay designed to target their DNA with a sixth molecular 
beacon probe, are also included in the Xpert MTB/RIF cartridge to serve as an internal control for sample 
processing and PCR amplification [97,161]. 
Fluorescent dyes and quenchers were developed to enable all six molecular beacons to be 
multiplexed within the same reaction [97,162]. 
3.2. Sample processing and integration into the GeneXpert 
The GeneXpert instrument system is a software-driven microfluidics-based cartridge processor and 
integrated fluorescence-based quantitative thermal cycler that processes biological samples to nucleic 
acids and performs real-time PCR [161].  
The Xpert cartridge consists of multiple chambers that are designed to hold all reagents, buffers, 
and enzymes, to process the biological sample, and to retain all waste. The cartridge has an attached tube 




3.3. Automated result analysis  
At the end of the real-time PCR, the data analysis algorithm integrates the results of the test and 
the control. Samples that are negative for Mtb and positive for the control B. globigii are reported as 
negative; samples that are negative for both Mtb and B. globigii are reported as invalid [97].  
A sample is reported as Mtb positive if at least two of the five rpoB probes are positive and within 
2 Ct of each other. Rifampin resistance is detected by the failure of one or more of the rpoB probes to 
hybridize properly to the rpoB amplicon. This is defined by a greater than 3.5 Ct difference between the 
earliest and latest rpoB probe signals, or if one to three rpoB probes did not produce any measurable 
signal at all [97]. 
3.4. Assay performance  
Assay performance was evaluated for sensitivity, specificity, and the ability to detect rpoB 
mutations [97].  
Sensitivity was assessed by evaluating the limit of detection (LOD) of the assay for purified Mtb 
genomic DNA, as well as for Mtb cells spiked in clinical sputum. LOD is defined as the amount of target 
material required for 95% probability of detection. Results showed an LOD of 4.5 genomes per reaction, 
and 131 colony forming units (CFU) per mL of sputum [97]. 
The specificity of the assay was confirmed by testing the ability to detect mutations in the rpoB 
gene associated with rifampin resistance, including DNA samples from an assortment of 6 wildtype 
(susceptible) and 23 RRDR mutant (resistant) clinical isolates, or artificial full-length double-stranded 
nucleotides, to test all regions of each molecular beacon probe. The results showed that all wild type and 
mutant samples were correctly identified by the assay [97]. 
Additional tests were completed to assess and validate the performance of the assay, showing rare 
cross-reactivity with other mycobacterial species, negligible impact of freeze-thawing the sample prior to 
performing the assay, and the ability to inactivate live Mtb to levels compliant with international 
decontamination standards [97]. Clinical studies showed an overall performance close to traditional 
culture-based methods of Mtb detection, with the advantage of providing results in a few hours instead 
of weeks [97]. 
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4. Conclusion 
4.1. My Role in the molecular diagnostics industry 
Even though I was not part of the team that developed the Xpert MTB/RIF assay, I was involved in 
its development and launch, and had to understand its mechanism and performance.  I was responsible 
for its ongoing quality after launch, any changes and upgrades to the production line and testing 
procedures, improvements, and validation.   
A production line is a vast network with many layers of complexity (Figure 3.2) across space and time. 
 
Figure 3.2. Generic overview of an assay production line and lifecycle management 
 
Each lot of a critical raw material, such as an enzyme, needs to be tested when it is received. For 
that one test only, test methods need to be developed and validated, and materials to be used in those 
tests need to be ordered and tested as well. The time that the raw material lasts in stock before it is 
incorporated into the assay needs to be determined, and then monitored. Each time a vendor changes a 
process or a small part of the raw material, an assessment of risk needs to be made, and re-validation of 
the assay may be needed. 
Processes need to be developed to integrate reagents, cartridge parts, software, and other pieces 
of information. These processes usually involve multiple departments and handoffs of material or 
information, which are at a higher risk for errors. Everything needs to be documented rigorously. These 
processes must be validated for accuracy and reliability and are subject to inspections and audits by 
regulatory agencies that oversee the quality of products in the medical field. These agencies vary from 
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country to country, and many have specific and dynamic labeling requirements, which result in strict and 
complex additional processes associated with labeling and distribution.  
Production and testing processes also must be made safe for the operators, as well as efficient and 
cost effective. Automation of production lines is common; it involves ambitious design and validation 
projects upfront that reduce manufacturing costs, errors, and safety incidents later. 
Many of these processes depart from Biotechnology, but many rely on it and leverage it; so, my 
team was generally composed of scientists with a deep knowledge of the real-time PCR assay and general 
molecular biology techniques, balanced with a strong pragmatic inclination for process development. I 
built and managed a team that was the liaison between all the departments involved with a product’s 
lifecycle and its scientific roots. I was accountable for the development of numerous processes and test 
methods, countless troubleshooting and improvement projects, and my work was fundamental to the 
company’s strategy and operations for over 15 years - across all of Cepheid’s line of over 25 assays, 
including MTB/RIF. 
4.2. Impact of TB molecular diagnostics in the world 
The Xpert MTB/RIF assay provided a rapid form of detection of MDR-TB with low-complexity and a 
sensitivity that approached culture methods, reducing the accurate detection time from weeks to hours 
[97]. 
In December 2010, the WHO publicly endorsed the Xpert MTB/RIF rapid-test as “a major milestone 
for global TB diagnosis and care” [163]. With affordability being a key concern, Cepheid and the 
Foundation for Innovative and New Diagnostics (FIND) negotiated of a 75% reduction in price for 116 low- 
and middle-income countries with endemic TB [163]. 
In 2012 the Bill and Melinda Gates Foundation announced a partnership with three other global 
humanitarian organizations, jointly providing funds to reduce the costs of the Xpert MTB/RIF test by more 
than 40% to 145 high-burden and developing countries affected by TB [164]. 
Diagnosis of TB is on a positive trend. In 2019, 7.1 million people were newly diagnosed with TB 
globally, up from 7.0 million in 2018 and largely increased from previous years [116]. This is mainly due 
to intensified efforts around testing. Despite these increases, there is still a large gap (2.9 million in 2019) 
between the number of people newly diagnosed and the 10 million estimated to have developed TB, due 
to underreporting and underdiagnosis [116]. Further improvements are needed to close the gap, by 
reducing underreporting, improving access to diagnosis, and ideally and achieve 100% detection. 
Global estimates by the WHO indicate that 10 million people fell ill with TB in 2019, down 2.3% 
from 2018 [116]. This estimation has been declining consistently in recent years, even if slowly, due to 
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global efforts that include early and effective detection, and allow patients to start as early as possible on 
the most effective treatment regimen [116].  
Cepheid continues to improve and expand its menu of Mtb diagnostic assays, including improved 
detection algorithms [98] and expansion to detection of XDR-TB [99], making a significant impact in the 
positive trends reported by the WHO. By mid-2017, 23 million Cepheid Xpert MTB/RIF tests had been 
procured in 130 countries [98]. Among countries reporting data to the WHO in 2019, an average of 63% 
of testing sites used the Xpert MTB/RIF assay, the most commonly used WHO-recommended rapid 




 General Conclusion 
My great-grandmother, Maria Silvina, died in her early thirties in the countryside of Portugal 
leaving behind my orphaned grandmother Maria Julia at the age of 11 with little more than a few loving 
memories. She died in 1918, like many around the word, from the great influenza pandemic, which my 
grandmother, who lived to see her three granddaughters into adulthood, always called the “pneumónica” 
in Portuguese.  
While I was writing this report of my work in the field of infectious lung diseases, another pandemic 
of viral origin affected the world like the great influenza: Covid-19. Pneumonia and tuberculosis have 
posed threats to public health for centuries, affecting young and old, rich or poor, and having a penchant 
for the frail. These bacterial lung infections are still of great relevance today and are of increased concern 
and when potentially involved in superinfections with viruses such as influenza or, recently, SARS-CoV-2. 
My contributions were small. I showed early evidence of the spread of two main clones of S. 
pneumoniae across the globe, identified eight genes potentially involved in virulence of Mtb, and helped 
assure a steady supply of effective Mtb diagnostics tests, with consistently high quality, and at the lowest 
possible cost. 
But the impact of my work, through the accumulation of other people’s efforts across the passing 
of time, was high. The two pneumococcus clones ended up starting a network for surveillance of 
pneumococcus spread and a new nomenclature; the eight Mtb genes and their involvement in virulence 
of TB are relevant for research in global ongoing efforts profoundly needed for treatment; and the Mtb 
diagnostic tests make a difference every day in developing countries and areas of endemic TB; they enable 
fast detection and enhance the outcomes of treatment, helping global efforts to eradicate the disease. 
 Through the stories that I heard so many times from my grandmother, I formed a personal 
connection with lung diseases and their effects in the world at large and on the life of one crucial 11-year-
old girl. My work is a small drop in the fight to improve the lives of human beings around the world. But 
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